

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

046124-5025

U.S. Application No.

Unassigned

09/555342

Box SEQ

International Application. No.	International Filing Date	Priority Date Claimed
PCT/JP98/05348	27 November 1998	27 November 1997

Title of Invention

**HUMAN FETUS CHONDROCYTE-DERIVED GENE**

Applicants For DO/EO/US

**Yukio KATO, Takeshi KAWAMOTO and Yasuhiko KOYANO**

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☒ Other items or information:
  - a. ☒ WIPO Publication WO99/28458 - (first page)
  - b. ☒ PCT/ISA/210
  - c. ☒ PCT/IB/304
  - d. ☒ PCT/IB/308
  - e. ☒ Computer readable copy of Sequence Listing  
☒ Paper Copy of Sequence Listing  
☒ Statement Accompanying Sequence Listing

09/555342

PCT/IP98/05348

046124-5025

15. [X] The following fees are submitted:

**Basic National Fee (37 CFR 1.492(a)(1)-(5)):**

Search Report has been prepared by the EPO or JPO.....\$840.00

International preliminary examination fee paid to

USPTO (37 CFR 1.482).....\$670.00

No international preliminary examination fee paid to

USPTO (37 CFR 1.482) but international search fee

paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00

Neither international preliminary examination fee

(37 CFR 1.482) nor international search fee

(37 CFR 1.445(a)(2)) paid to USPTO.....\$970.00

International preliminary examination fee paid to USPTO

(37 CFR 1.482) and all claims satisfied provisions

of PCT Article 33(2)-(4).....\$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 840.00**

Surcharge of \$130.00 for furnishing the oath or declaration later than

[ ] 20 [ ] 30 months from the earliest claimed priority date

(37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	Rate	
Total Claims	44 - 20 =	0	X \$18.00	\$432.00
Independent Claims	5 - 3 =	0	X \$78.00	\$156.00
Multiple dependent claim(s) (if applicable)			+\$260.00	\$260.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 1,688.00</b>

Reduction by 1/2 for filing by small entity, if applicable. Verified

Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)

-\$

**SUBTOTAL = \$ 1,688.00**

Processing fee of \$130.00 for furnishing the English translation later

than [ ] 20 [ ] 30 months from the earliest claimed priority date

(37 CFR 1.492(f)).

+\$

**TOTAL NATIONAL FEE = \$ 1,688.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The

assignment must be accompanied by an appropriate cover sheet

(37 CFR 3.28, 3.31).

\$40.00 per property

+\$40.00

**TOTAL FEES ENCLOSED = \$ 1728.00**

Amount to be

refunded

\$

charged

\$

- a. [ ] A check in the amount of \$-0- to cover the above fees is enclosed.
- b. [X] Please charge my Deposit Account No. 50-0310 in the amount of \$1,728.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. [X] **Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 CFR §1.16 and §1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.

Customer No. 009629

SEND ALL CORRESPONDENCE TO:

Morgan, Lewis &amp; Bockius LLP

1800 M Street, N.W.

Washington, D.C. 20036

(202) 467-7000

*Elizabeth C. Weimar*

Elizabeth C. Weimar

Reg. No. 44,478

Submitted: May 26, 2000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yukio KATO et al. )  
 )  
 U.S. National Phase Application )  
 Filed: May 26, 2000 )  
 )  
 U.S. Application No.: To Be Assigned )  
 )  
 Date of National )  
 Stage Entry: Concurrently ) Art Unit: Unassigned  
 )  
 Based on PCT/JP98/05348 ) Examiner: Unassigned  
 )  
 Filed: June 10, 1999 )  
 )  
 For: HUMAN FETUS CHONDROCYTE- )  
 DERIVED GENE )

Assistant Commissioner for Patents  
 Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to examination in the above-identified application  
 please enter the following amendments:

IN THE CLAIMS:

Cancel claims 1-10.

Add the following claims 11-24:

11. A protein specifically expressed in differentiated chondrocytes, comprising an ezrin-like domain, a Db1 domain, and a pleckstrin domain.

12. A protein having an amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing.

13. A protein comprising an amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing in which one to several amino acids have been deleted, substituted or added, the protein being specifically expressed in differentiated chondrocytes, and the protein being such that

(1) the amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 1st to 374th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 1st to 374th amino acids in the SEQ ID NO: 2,

(2) the amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 544th to 737th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 544th to 737th amino acids in the SEQ ID NO: 2, and

(3) the amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 764th to 854th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 764th to 854th amino acids in the SEQ ID NO: 2.

14. DNA encoding the protein according to claim 11.

15. DNA encoding the protein according to claim 12.

16. DNA encoding the protein according to claim 13.

17. A gene comprising DNA shown in the following (a) or (b):

(a) DNA comprising a nucleotide sequence ranging from the 49th to 3,183rd bases in a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing; and

(b) DNA which is hybridized under stringent conditions with DNA having a nucleotide sequence ranging from the 49th to 3,183rd bases in a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, and which encodes a protein specifically expressed in differentiated chondrocytes.

18. DNA having a part of or all of a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, or having a nucleotide sequence complementary to the part of or all of the nucleotide sequence.

19. An antibody against the protein according to claim 11.

20. An antibody against the protein according to claim 12.

21. An antibody against the protein according to claim 13.

22. A kit for screening a regulator of cell differentiation induction, the kit comprising at least one of the following (a) to (c) as an active ingredient:

(a) the protein according to any one of claims 11 to 13;

(b) the DNA according to any one of claims 14 to 18; and

(c) the antibody according to any one of claims 19 to 21.

23. A method for screening a regulator of cell differentiation induction, the method comprising using the kit according to claim 22.

24. The method for screening claimed in claim 23, wherein the regulator of cell differentiation induction is an anti-tumor agent.

**REMARKS**

No new matter has been introduced by this Preliminary Amendment, which is being submitted to remove improper multiple dependencies.

If there are any additional fees due in connection with the filing of this Preliminary Amendment, please charge the fees to our Deposit Account No. 50-0310.

Respectfully submitted  
**MORGAN, LEWIS & BOCKIUS LLP**

*Elizabeth C. Weimar*

Elizabeth C. Weimar  
 Reg. No. 44,478

Dated: May 26, 2000  
**MORGAN, LEWIS & BOCKIUS LLP**  
 1800 M Street, N.W.  
 Washington, DC 20036  
**202-467-7812**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Yukio KATO et al. )  
)  
U.S. National Phase Application No.: Unassigned ) Group Art Unit: Unassigned  
)  
Date of National Stage Entry: May 26, 2000 ) Examiner: Unassigned  
)  
International Applicaton No.: PCT/JP98/05348 )  
)  
International Filing Date: November 27, 1998 )  
)  
For: HUMAN FETUS CHONDROCYTE- )  
DERIVED GENE )

Commissioner for Patents  
Washington, D.C. 20231  
**BOX SEQUENCE**

**STATEMENT ACCOMPANYING SEQUENCE LISTING**

Dear Sir:

The undersigned hereby states upon information and belief that the Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

Dated: May 26, 2000

By: Elizabeth C. Weimar  
Elizabeth C. Weimar

**CUSTOMER NO. 009629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
**1800 M Street, N.W.**  
**Washington, D.C. 20036**  
**(202) 467-7000**

11/pR+S

526 Rec'd PCT/PTO 26 MAY 2000

**Description****Human Fetus Chondrocyte-Derived Gene****5 Technical Field**

This invention relates to a gene expressed specifically in differentiated human chondrocytes, a protein encoded by the gene, and an antibody against the protein.

**10 Background Art**

No methods for monolayer culturing human chondrocytes in a differentiated state have been established. This has made it difficult to search for a gene specifically expressed in differentiated chondrocytes, and analyze the properties of a protein encoded by the gene.

**15 Disclosure of the Invention**

Recently, the inventor of the present invention has discovered a method of monolayer culture for human chondrocytes in a differentiated state (M. Shen, T. Kawamoto, W. Yan, K. Nakamasu, M. Tamagami, Y. Koyano, M. Noshiro, and Y. Kato, Biochemical and Biophysical Research Communications 236, 294-298 (1997)). The inventor has found that a gene specifically expressed in human chondrocytes in a differentiated state can be searched for by using such a culture method.



Based on these findings, the inventor looked for genes different in expression between human chondrocytes in a differentiated state and chondrocytes in a dedifferentiated state, and found out a gene specifically expressed in former cells. This finding led to the present invention.

That is, the invention provides a gene expressed specifically in differentiated cells (cells in various animals, especially cells including chondrocytes and human chondrocytes), a protein encoded by the gene, and an antibody against the protein. The invention also provides the gene or its fragment, nucleotide sequences complementary to them, the protein or its mutant product, fragments thereof, a kit and a method for detecting differentiated chondrocytes with the use of the antibody, or a kit and a method for screening a regulator of cell differentiation induction.

More particularly, the invention provides [1] a protein specifically expressed in differentiated chondrocytes, including an ezrin-like domain, a Db1 domain, and a pleckstrin domain. The invention also provides [2] a protein having an amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing. The invention also provides [3] a protein comprising the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing in which one to several amino acids have been deleted, substituted or added, the protein being specifically expressed in differentiated chondrocytes, and the protein

being such that (1) an amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 1st to 374th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 1st to 374th amino acids in the SEQ ID NO: 2, (2) an amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 544th to 737th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 544th to 737th amino acids in the SEQ ID NO: 2, and (3) an amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 764th to 854th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 764th to 854th amino acids in the SEQ ID NO: 2.

Further, the invention provides [4] DNA encoding the protein described in any one of the [1] to [3]. The invention also provides [5] a gene comprising DNA shown in the following (a) or (b): (a) DNA comprising a nucleotide sequence ranging from the 49th to 3,183rd bases in a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing. (b) DNA which is hybridized under stringent conditions with DNA having a nucleotide sequence ranging from the 49th to 3,183rd bases in a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, and which encodes a protein

specifically expressed in differentiated chondrocytes. The invention also provides [6] DNA having a part of or all of a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, or having a nucleotide sequence complementary to them.

Further, the invention provides [7] an antibody against the protein described in any one of [1] to [3].

Further, the invention provides [8] a kit for detecting differentiated chondrocytes, characterized by containing at least one of the following (a) to (c) as an active ingredient: (a) The protein described in any one of [1] to [3]. (b) The DNA described in any one of [4] to [6]. (c) The antibody described in [7]. The invention also provides [9] a method for detecting differentiated chondrocytes, characterized by using the kit described in [8].

Further, the invention provides [10] a kit for screening a regulator of cell differentiation induction, characterized by containing at least one of the following (a) to (c) as an active ingredient: (a) The protein described in any one of [1] to [3]. (b) The DNA described in any one of [4] to [6]. (c) The antibody described in [7]. The invention also provides [11] a method for screening a regulator of cell differentiation induction, characterized by using the kit described in [10].

Further, the invention provides [12] a screening method in which the regulator of cell differentiation

induction described in [11] is an anti-tumor agent.

The amino acid sequence of the protein according to the present invention contains three domains, i.e., ezrin-like domain, Dbl homology (DH) domain, and pleckstrin homology (PH) domain, arranged in this order from the N-terminus in one molecule. Hence, this novel protein may be a very important factor for controlling the activity of an Rho family which exists near the cell membrane and regulates the function of the actin-based cytoskeleton responsible for the maintenance of cell shape and cell motility.

It becomes possible, moreover, to develop a drug for regulating cell differentiation induction or the proliferation of cancer, by activating or inhibiting the function of the protein according to the invention.

The invention also makes it possible to develop a probe indispensable for the analysis of the mechanism of cartilage differentiation or degeneration. The invention further permits the development of gene therapies of osteoarthritis and rheumatoid arthritis.

#### Brief Description of the Drawings

Fig. 1 is a view showing a nucleic acid nucleotide sequence of CDEP cDNA, and an amino acid sequence deduced therefrom, in which ezrin-like domain is indicated by an open frame, Dbl homology (DH) domain is underlined, pleckstrin homology (PH) domain is double-underlined, an

asterisk downstream from a protein coding region represents a stop codon, a poly(A) addition signal is indicated by a dashed line, and a poly(A) addition site is indicated by a triangle;

5            Fig. 2A is an electrophoretogram showing the results of northern blotting analysis of CDEP mRNA in various fetal human tissues, in which Ch- denotes a Bt2cAMP-untreated fibroblastic chondrocytes, Ch+ denotes a Bt2cAMP-dependent differentiated chondrocytes; Br denotes brain; He denotes heart; Li denotes liver; Sp denotes spleen; In denotes intestine; Lu denotes lung; Te denotes testis; Pl denotes placenta; Mu denotes muscle, and the size of CDEP mRNA is expressed in kb;

10            Fig. 2B is an electrophoretogram showing the results of northern blotting analysis of CDEP mRNA in various adult tissues, in which Ch- denotes a Bt2cAMP-untreated fibroblastic chondrocytes, Ch+ denotes a Bt2cAMP-dependent differentiated chondrocytes; Br denotes brain; He denotes heart; Li denotes liver; Sp denotes spleen; In denotes intestine; Lu denotes lung; Te denotes testis; Pl denotes placenta; Mu denotes muscle, and the size of CDEP mRNA is expressed in kb;

15            Fig. 3 is a view showing the arrangement of an ezrin-like domain and a Db1 homology (DH) domain, and comparisons among ezrin-like domain of human CDEP, ezrin, and band 4.1, in which the residues conserved with respect

to CDEP are indicated in bold type;

Fig. 4 is a view showing comparisons among DH domain of human CDEP, human Db1, rat Ost, mouse Est2, and human FGD1, in which the residues conserved with respect to CDEP are indicated in bold type;

Fig. 5 is a schematic view showing the relation between CDEP and other proteins;

Fig. 6 is an electrophoretogram showing the results of RT-PCR (reverse transcription PCR) of mRNA of type II collagen, aggrecan, cartilage matrix protein (CMP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (upper row), DEC1 and CDEP (lower row), expressed in response to Bt<sub>2</sub>cAMP in fetal human chondrocytes, in which cAMP+ represents the presence of Bt<sub>2</sub>cAMP, while cAMP- represents the absence of Bt<sub>2</sub>cAMP;

Fig. 7 shows the expression of CDEP, type X collagen, ALP, and aggrecan in each of R, G1, G2 and G3 in Example 4;

Fig. 8 shows the expression of CDEP in each stage of differentiated chondrocytes, and the effect of PTH addition on the expression;

Fig. 9 shows the time courses of CDEP expression after addition of Bt<sub>2</sub>cAMP and PTH;

Fig. 10 shows the time course of CDEP expression after addition of PTH;

Fig. 11A shows the results of immunofluorescence

staining (under CNF2(-) conditions) indicating the localization of CDEP in the cell; and

Fig. 11B shows the results of immunofluorescence staining (under CNF2(+) conditions) indicating the localization of CDEP in the cell.

### Best Mode for Carrying Out the Invention

(Protein, DNA encoding the protein)

The protein provided by the present invention is derived from DNA discovered by the invention that is set forth in SEQ ID NO: 1 in the sequence listing. A preferred example of the protein has an amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing. As will be described later on in Examples, this sequence was obtained for the first time as a result of search for a gene expressed specifically in human chondrocytes in a differentiated state. The protein having this derived amino acid sequence is called CDEP in the present specification. As will be described below, proteins having different amino acids from those of the above protein, but having substantially the same function as this protein are also collectively called CDEP.

The total nucleotide sequence obtained as the gene encoding the protein CDEP (the gene will be referred to as CDEP cDNA) is described in SEQ ID NO: 1 in the sequence listing. The correspondences with amino acids deduced from the

resulting nucleotide sequence are set forth in SEQ ID NO: 1 in the sequence listing, and Fig. 1 (amino acids are showed as three characters).

CDEP cDNA includes an open reading frame of 3135 bp starting with the first ATG codon existent on the 49th nucleotide. Since an in-frame stop codon is present upstream from the 5'-region (the 34th nucleotide), moreover, the first ATG is defined as an initiation codon. Thus, CDEP is assumed to comprise 1,045 amino acid residues, and its molecular weight is calculated at 118.6 kDa.

The amino acid sequence of CDEP deduced from the above nucleotide sequence is described in SEQ ID NO: 2 in the sequence listing, and Fig. 1. Based on the resulting amino acid sequence, the amino acid sequence of CDEP is found to lack a signal peptide for secretion, and a hydrophobic region of a transmembrane or membrane-bound domain.

At least three polyadenylation signals and polyadenylation sites are found to exist. The total length of 3287 bp, 3306 bp or 3442 bp, excluding the poly(A) tract, is consistent with the size of mRNA (3.5 kb, indicated by an arrow as 3.5 kb in Fig. 2(a)) determined by northern blotting analysis to be described below.

Homology search of the above amino acid sequence by the use of protein database has shown that the CDEP protein includes all of three functional domains, i.e., ezrin-like domain, DH domain, and PH domain (Figs. 1, 3, 4). No protein



has been known which possesses all of ezrin-like domain, DH domain, and PH domain.

The ezrin-like domain that CDEP has refers to the one conserved in a band 4.1 superfamily, including ezrin, radixin, moesin, and band 4.1 that have been known. Fig. 3 shows the homology of the ezrin-like domain of CDEP to them. The ezrin-like domain of CDEP has homology of 27.5% to ezrin, and homology of 43.7% to band 4.1.

A protein such as ezrin is believed to play the role of a linker protein between the cytoskeleton and the cell membrane. Of some proteins recently reported, including an ezrin-like domain in the N-terminal region, merlin is known to be an tumor suppressor molecule which causes neurofibroma type 2, and PTPMEG1 and PTPH1 are known to be members of a cytoplasmic protein tyrosine phosphatase (PTP) family. These proteins are known to take part in the transmission of signals from outside of the cell to the inside of the cell at the boundary between the cell membrane and the cytoskeleton. A notable fact is that ezrin, radixin, and moesin (these are called ERM proteins) bind to a cytoplasmic domain of CD44, a hyaluronate receptor, through their N-terminal region. Also noticeable is that the binding of the ERM proteins to CD44 is enhanced by GTP $\gamma$ S, and markedly suppressed by C3 toxin, a specific inhibitor of Rho. As noted from these facts, GTP-Rho is required for the formation of a CD44/ERM protein complex.

The CDEP protein of the invention also has the DH domain and the PH domain. The Rho GEF family, including Db1, Ost, Ect2 and Lbc which are oncogene products, and FGD1 which is a causative gene for faciogenital dysplasia, is also known to include a DH domain, and to be bound directly to a PH domain (DH-PH sequence) at the C-terminus. The homology of CDEP in terms of DH domain is 22.9% for Db1, 22.9% for Ost, 22.3% for Ect2, and 25.6% for FGD1 (Fig. 4).

Rho GEF is known to convert GDP-Rho (inactive type), in particular, into GTP-Rho (active type), while Ras GEFs are known to convert GDP-Ras into GTP-Ras. Rho and Ras belong to a small GTP-binding protein superfamily, and are known to take part in intracellular signal transduction. The superfamily is divided into five subfamilies, i.e., Ras, Rho, Rab, Arf, and other. The Rho subfamily (Rho, Rac, and Cdc42) is known to control the morphology, migration, aggregation and adhesion of cells by contraction of actin filaments. It is also known that some regulators of Rho, such as GEFs and GTPase-activating proteins (GAPs), are present upstream in the Rho cascade.

It is further known that the DH-PH domain is necessary for Rho GEF activity, while the Cdc-25 domain is necessary for Ras GEF activity; some of Ras GEF family members, such as Ras-GRF and Sos, have Ras GEF activity, but have no Rho GEF activity, even though they have DH-PH domain in addition to Cdc-25 domain.

As described above, CDEP of the invention is characterized by lacking the Cdc-25 domain and containing the DH-PH domain. Thus, CDEP is one of the members of the Rho GEF family, rather than the Ras GEP family.

5           The ERM proteins having the ezrin-like domain are known to be involved in signal transduction leading to morphological changes of cells through the formation of a CD44/ERM/actin complex. Formation of this complex requires the activity of Rho by Rho GEF. CDEP obtained in the invention  
10 is found to be a very unique protein containing an ezrin-like domain and an Rho GEF-like domain in one molecule (Fig. 5). This is suggestive of a possibility that this substance will modify signal transduction in the CD44 path and/or a path mediated by other receptor. Furthermore, many members of  
15 the Rho GEF family become oncogenes for lack of the N-terminal region. This finding suggests that CDEP plays an important role in controlling the adhesion, diffusion, migration, proliferation, and differentiation of cells, including chondrocytes.

20           Therefore, the CDEP protein of the invention includes not only a protein having the amino acid sequence set forth in SEQ ID NO: 2, but also a protein having a novel amino acid sequence comprising the amino acid sequence of SEQ ID NO. 2 in which one to several amino acids have been deleted,  
25 substituted or added, the novel amino acid sequence having an ezrin-like domain, a DH domain, and a PH domain in the

molecule.

Particularly, the CDEP protein includes a protein in which an amino acid sequence ranging from the 1st to 373rd amino acids in SEQ ID NO: 2 (called ezrin-like domain) has  
5 homology of 70% or more (preferably 85% or more) to the amino acid sequence of the SEQ ID NO: 2, in which an amino acid sequence ranging from the 544th to 737th amino acids in SEQ ID NO: 2 (called DH domain) has homology of 70% or more (preferably 85% or more) to the amino acid sequence of the  
10 SEQ ID NO: 2, and in which an amino acid sequence ranging from the 764th to 854th amino acids in SEQ ID NO: 2 (called PH domain) has homology of 70% or more (preferably 85% or more) to the amino acid sequence of the SEQ ID NO: 2.

The protein having such amino acid sequences has  
15 substantially the same domains as ezrin-like, DH and PH domains characteristic of CDEP, and is thus presumed to have substantially the same biochemical functions as does CDEP.

The CDEP protein, which has a different amino acid sequence from that of CDEP having the amino acid sequence  
20 described in SEQ ID NO: 2 in the sequence listing and which has substantially the same functions, can be obtained by a method for replacing, deleting, or inserting particular amino acid residues in the amino acid sequence described in SEQ ID NO: 2 in the sequence listing. Such a method is  
25 not restricted, and a publicly known method can be used preferably as this method. For example, the CDEP protein

can be formed by introducing a mutation, such as substitution, deletion or insertion of nucleotide, into the nucleotide sequence by a publicly known method such as site-directed mutagenesis, and people skilled in the art can easily select the type of the mutant protein. That is, derivatives having functions comparable to those of particular proteins can be prepared by any methods of chemical peptide synthesis well known in the art, or ordinary genetic engineering methods, for instance, recombinant DNA technologies based on DNA sequence as disclosed in Sambrook et al., Molecular Cloning, Cold Spring Harbour Laboratory Press, New York, USA, Second Edition, 1989. Concretely, the method described, for example, in H. Neurath R.L. Hill, "The Proteins" (Academic Press, New York, 1979, especially in Fig. 6 on page 14) is usable. Substitutions that occur most usually are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu and Asp/Gly, and vice versa.

Thus, DNA encoding the CDEP protein includes not only that coding for a protein having the amino acid sequence set forth in SEQ ID NO: 2, but also DNA encoding a protein having a novel amino acid sequence comprising the amino acid sequence of SEQ ID NO. 2 in which one to several amino acids have been deleted, substituted or added, the novel amino acid sequence having an ezrin-like domain, and DH and PH domains in the molecule.

Particularly, the above DNA includes DNA encoding a protein in which an amino acid sequence ranging from the 1st to 373rd amino acids in SEQ ID NO: 2 (ezrin-like domain) has homology of 85% or more to the amino acid sequence of the SEQ ID NO: 2, in which an amino acid sequence ranging from the 544th to 737th amino acids in SEQ ID NO: 2 (DH domain) has homology of 85% or more to the amino acid sequence of the SEQ ID NO: 2, and in which an amino acid sequence ranging from the 764th to 854th amino acids in SEQ ID NO: 2 (PH domain) has homology of 85% or more to the amino acid sequence of the SEQ ID NO: 2.

The DNA "encoding or coding for a protein" refers to DNA, if double-stranded, in which one of the complementary two strands has a nucleotide sequence coding for the protein. The DNA of the invention further includes DNA comprising a nucleotide sequence ranging from the 49th to 3183rd bases in the nucleotide sequence set forth in SEQ ID NO: 1, or a nucleotide sequence complementary thereto.

The invention also includes a DNA sequence encoding the CDEP protein, a DNA sequence including a strand complementary to the above sequence, or these sequences, a DNA sequence hybridized under standard conditions with the sequence or a fragment derived therefrom, and a DNA sequence which is not hybridized under standard conditions with the DNA sequence because of degeneracy of the genetic code, but which encodes a polypeptide having exactly the

The "standard conditions" for hybridization refer to conditions generally used by people skilled in the art to detect specific hybridization signals, and those conditions mentioned, for example, in Sambrook et al., Molecular Cloning, Cold Spring Harbour Laboratory Press, New York, USA, Second Edition, 1989, preferably, so-called stringent hybridization-non-stringent washing conditions known among people skilled in the art and stated by Sambrook et al., more preferably, so-called stringent hybridization-stringent washing conditions. The stringent conditions preferably used in the invention are conditions under which a so-called specific hybrid is formed and a non-specific hybrid is not formed. It is difficult to express these conditions clearly as numerical values. However, concrete conditions include a temperature in the range of from the  $T_m$  of a hybrid of nucleic acids with high homology, e.g., a hybrid of completely matching nucleic acids, to a temperature  $20^\circ\text{C}$  lower than the  $T_m$ , or conditions at which DNA's having homology of 80% or more are hybridized, but nucleic acids having lower homology are not hybridized.

Furthermore, it is included in the invention to provide a DNA sequence which can be prepared by polymerase chain reaction (PCR) with the use of primers, designed based on the DNA sequence of SEQ ID NO: 1 of the sequence listing disclosed in the present specification, in accordance with

the method well known in the art.

5 The DNA according to the invention can be synthesized on the basis of one of the nucleotides sequences of the DNA that have been determined by the invention as shown in Examples to be offered later on. The DNA can also be obtained from chromosomal DNA by PCR or hybridization using oligonucleotide primers or a probe prepared based on the nucleotide sequence. Alternatively, the DNA can be obtained by performing RT-PCR using cartilage mRNA, or by screening a cDNA library of cartilage or the like with the use of a polynucleotide, which has a nucleotide sequence encoding all or part of CDEP protein, as a probe.

10 The CDEP protein of the invention can be produced by inserting the aforementioned DNA of the invention into a publicly known expression vector to construct a recombinant plasmid, introducing this recombinant plasmid into a cell to obtain a transformant, culturing the transformant in a suitable medium to form and accumulate the protein of the invention in the culture, and collecting the protein from the culture.

15 As the cell and expression vector, a host-vector system usually used in the expression of a foreign protein can be used. Examples are combinations of procaryotic cells, such as Escherichia coli, and suitable expression vectors, and combinations of eucaryotic cells, such as mammalian cells, and suitable expression vectors. The culture media and



culture conditions are suitably selected in harmony with the cells used.

The protein of the invention may be expressed as a fusion protein combined with other protein. Moreover, the protein of the invention may be expressed with its entire length, or may be expressed partially as a partial peptide.

The culture refers to a culture medium, and cells in the culture medium. Collection of the protein of the invention from the culture can be performed by a publicly known protein purification method using the activity, etc. of the protein of the invention as indicators.

If desired, the protein of the invention can be isolated from a heterogenetic organism by using the aforementioned nucleotide sequence information (in consideration of the codons used), by colony hybridization or southern blot hybridization using a probe synthesized in accordance with an amino acid sequence deduced from the nucleotide sequence, or by polymerase chain reaction (PCR) using primers synthesized by the information.

(Antibody)

An antibody which can bind to the protein of the invention (hereinafter referred to as the antibody of the invention) can be prepared by the customary method using the protein of the invention as an antigen. The antibody of the invention may be polyclonal or monoclonal.

The protein of the invention may be used, unchanged,

as an antigen, but is preferably used as an antigen after being joined to a carrier protein, such as keyhole limpet hemocyanin, bovine serum albumin, or ovalbumin, and/or in combination with an adjuvant.

5           The polyclonal antibody can be obtained by immunizing an animal, such as mouse, rabbit, guinea pig or sheep, with intraperitoneal or intravenous injection of the antigen, and taking the serum from the immunized animal.

10           The monoclonal antibody can be obtained, for example, in the following manner: An animal, such as mouse, rabbit, guinea pig or sheep, is immunized with subcutaneous, intraperitoneal or intravenous injection of the antigen. Then, the spleen or lymph node is removed, and a cell is taken therefrom. The cell is fused with a myeloma cell derived  
15           from an animal, preferably, allogeneic to the immunized animal to establish a hybridoma. From the resulting hybridoma, a cell strain which continuously produces specific antibodies to the antigen is chosen by repeating screening and cloning. The so selected cell strain is cultured in a  
20           suitable medium, and monoclonal antibodies are produced in the medium. Alternatively, the cell strain is cultured in vivo, e.g. intraperitoneally in the mouse, to produce monoclonal antibodies in ascitic fluid or the like.

25           Methods for purification of the resulting polyclonal and monoclonal antibodies include, for example, salting out by ammonium sulfate, ion exchange chromatography using a

DEAE cellulose column or the like, affinity chromatography using a protein A column or the like, and immunoadsorbent chromatography. The antibody of the invention can be detected, for example, by immunoassay using the protein of the invention and a labeled antibody.

The antibody of the invention may be a fragmented one as long as the antigen-binding site (Fab) is conserved. An example of the fragmented antibody is an Fab-containing fragment obtained by decomposing the antibody with a protease which does not decompose the antigen-binding site, such as papain.

The antibody of the invention may have been labeled by being bound to a labeling substance. The labeling substance is not restricted, if normally usable for labeling a protein. Its examples are enzymes, isotopes, and fluorescent materials.

A method according to the invention for screening a regulator of cell differentiation induction using the protein of the invention may, for example, comprise adding the substance in question to a cell having differentiation potency, such as tetracarcinoma, and investigating what actual changes occurred in the cell, for instance, whether the cell differentiated, based on the shape of the cell and/or the expression of a marker gene. Alternatively, the screening method of the invention may be to add various medicines, which have been chemically synthesized, to the

cell, and search for agents which can change the amount of expression of CDEP.

(Kit for detection of differentiated chondrocytes, Method for detection of differentiated chondrocytes)

5           The method of the invention for detection of differentiated chondrocytes uses the aforementioned gene of the invention which is specifically expressed in differentiated chondrocytes.

10           Concretely, (a) the CDEP protein of the invention is used in a publicly known method to enable differentiated chondrocytes to be specifically detected. Alternatively, (b) the DNA of the invention, or its derivative is used in a publicly known method to enable differentiated chondrocytes to be specifically detected. Further alternatively, (c) the  
15           antibody of the invention is used in a publicly known method to enable differentiated chondrocytes to be specifically detected. Any combination of these methods can be used as the method of the invention.

(Method for screening a regulator of cell differentiation induction, Kit for screening a regulator of cell  
20           differentiation induction)

25           The method of the invention for screening a regulator of cell differentiation induction uses the aforementioned gene of the invention which is specifically expressed in a differentiated chondrocytes.

Concretely, (a) the CDEP protein of the invention is

used in a publicly known method to enable a regulator of cell differentiation induction to be screened.

Alternatively, (b) the DNA of the invention is used in a publicly known method to enable a regulator of cell

5 differentiation induction to be screened. Further alternatively, (c) the CDEP protein of the invention is used in a publicly known method to enable a regulator of cell differentiation induction to be screened. Any combination of these methods can be used as the method of the invention.

10 More concretely, the method for screening an anti-tumor agent as a regulator of cell differentiation induction may, for example, be to add various chemically synthesized agents to a cell cancerized by introduction of the aforesaid CDEP cDNA deficient on the N-terminal side, and search which of the agents return the cell to normal.

15 The invention further includes a regulator of cell differentiation induction which can be obtained by the above screening method.

(Biological functions of CDEP)

20 The biological functions of CDEP obtained by the invention are summarized here. CDEP has an ezrin-like domain, and DH and PH domains in one molecule. In this view, CDEP may work by the following mechanism: The Ezrin-like domain dissociates Rho GDI from Rho, and then the DH and PH domains perform GDP-GTP exchange reaction in one molecule to regulate  
25 the activity of Rho, thereby controlling cell shape. Hence,

CDEP is considered to be a very advantageous factor for activation of Rho among Rho GEFs.

#### Examples

The present invention will now be described with reference to Examples to be offered below. PCR primers used in the Examples were synthesized by an ordinary automatic method of synthesis.

For type II collagen: CATACCGGTAAGTGGGGCAAGACTG,

TGCCCAGTTCAGGTCTCTTA

For aggrecan: TGCTACTTCATCGACCCCAT, AAAGACCTCACCTCCATCT

For CMP: GTCGATTACGTGGAGAGCTA, ATGAACTTCTTCACCAGCTC

For GAPDH: GTCAAGGCTGAGAACGGGAA, TCCACCACCCTGTTGCTGTA

For DECl: ATCAGACCCAGCTCCCAAAG, CACAGACCCAGCTCCCAAAC

For CDEP: CCTTCAGGAAAACCTCGTGTC, TTGGAGTTGTGTGTGGTCAG

For CDEP cDNA fragment: GCCAAAATAGTCACCTTCCACGAGG,

CCTTCAGGAAAACCTCGTGTC, AAACGRAAGAAYGTRTGRTGYTCWACACA,

TTCCAGCTCCTAGAGATTGC, TCGTCTTCGCTCTCCTCAAT,

CGGGTAACAAGCAGGCGGACGGA

(Example 1)

Culture of differentiated chondrocytes was performed in the following manner in accordance with the method described in Biochemical and Biophysical Research

Communications 236, 294-298 (1997), M. Shen, T. Kawamoto, W. Yan, K. Nakamasu, M. Tamagami, Y. Koyano, M. Noshiro,

and Y. Kato:

From a human fetus spontaneously aborted at about 25 weeks of pregnancy (obtained from Norman Bethune University of Medical Sciences), an epiphyseal cartilage on the femur side of the knee joint was obtained. From this cartilage, chondrocytes were isolated by the same method as described in Simomura et al. (1975), *Calcif. Tissue Res.* 19, 179-187, except that cartilage slices were incubated for 3 hours in an  $\alpha$ -modified Eagle's medium ( $\alpha$ -MEM) containing 3 mg/ml of collagenase (type IA, Sigma). The obtained cells were seeded on type I collagen coated dishes at a density of  $1 \times 10^5$  cells/dish. The cells were cultured in  $\alpha$ -MEM (10 ml/dish) containing 10% bovine fetal serum, 50  $\mu$ g/ml ascorbic acid, 32 units/ml of penicillin, and 40  $\mu$ g/ml of streptomycin. When the cells became subconfluent, dibutyryl cAMP (dbcAMP) (1 mM) was added to the culture medium. The cells were cultured for 2 weeks or more in the presence and absence of dbcAMP, and then morphological observation of the cells was made. Also, the cells were harvested, fixed with ethanol, and stained with toluidine blue.

The chondrocytes cultured in the presence of dbcAMP took a spherical form, and were rich in extracellular matrix. Whereas the chondrocytes cultured in the absence of dbcAMP were spindle-shaped, similar to fibroblasts, and deficient in extracellular matrix.

Staining with toluidine blue, which selectively

stains sulfated proteoglycan, satisfactorily stained the chondrocytes cultured in the presence of dbcAMP, but scarcely stained the chondrocytes cultured in the absence of dbcAMP.

The expression of mRNA of type II collagen, aggrecan and CMP as molecule markers was examined by RT-PCR. The expression of the molecule marker in the presence of dbcAMP was compared with that in the absence of dbcAMP. It was suggested that a differentiated state was maintained in the presence of dbcAMP (Fig. 6).

Thus, the chondrocytes cultured in the presence of dbcAMP were admitted to maintain a differentiated state as cartilage, namely, a differentiated phenotype.

The above effect of dbcAMP was examined for dose dependency. This effect was found to increase dose dependently, and peaked at 0.3 to 0.5 mM.

Chondrocytes were cultured in the same manner as described above, except that bFGF (0.4 ng/ml) and TGF- $\beta$  (3 ng/ml) were used instead of dbcAMP. bFGF and TGF- $\beta$  are reported to stabilize or stimulate the expression of the differentiated phenotype of rabbit and chicken chondrocytes. The expression of the differentiated phenotype of the human-derived chondrocytes was not maintained with the use of bFGF and TGF- $\beta$ .

(Example 2) Gene specifically expressed in chondrocytes in a differentiated state



From the chondrocytes cultured in the presence of dbcAMP and in the absence of dbcAMP as described in Example 1, total RNA was extracted by the guanidine thiocyanate/cesium trifluoroacetate method. Poly(A)<sup>+</sup>RNA was concentrated using Oligotex-dT30 (Roche). Clones encoding mRNA, which is expressed in differentiated chondrocytes (+dbcAMP), but not in dedifferentiated chondrocytes (-dbcAMP), were selected by subtractive hybridization. That is, cDNA derived from mRNA of the differentiated chondrocytes was hybridized with an excess amount of cDNA derived from mRNA of the dedifferentiated chondrocytes, by use of PCR Select cDNA Subtraction Kit (Clontech). cDNA which is not hybridized, namely, which is expressed in a differentiated state, was amplified by suppression PCR. The resulting PCR product was cloned into a T tail vector pGEM-T (Promega), and nucleotide sequencing of about 120 clones was performed. For further analysis, one clone was selected, and the corresponding protein product was named CDEP.

Fig. 2A and Fig. 2B show the results of northern blotting analysis of CDEP mRNA expression in various human fetal tissues by the use of a 1.6 kb fragment of CDEP as the probe. Here, the transcript of 5.0 kb was also detected by northern blotting analysis. This finding suggests that in addition to the PCR product derived from 3.5 kb mRNA, a larger band induced from 5.0 kb mRNA probably hybridizable

with the CDEP probe was found in RACE-PCR as well. However, the nucleotide sequencing of the product corresponding to the transcript of 5.0 kb has not been performed yet.

The expression pattern of CDEP mRNA in cultured chondrocytes and various human tissues by northern blotting analysis showed that two main bands, 3.5 kb and 5.0 kb, were detected in cyclic AMP dependent differentiated chondrocytes, as illustrated in Fig. 2A, but they were not detected in fibroblasts without cyclic AMP. In fetal tissues, the highest level of CDEP mRNA was observed in the brain and the spleen, and low to intermediate levels of CDEP mRNA were noted in the heart, liver and intestine (Fig. 2A). In adult tissues, the amount of expression was intermediate in the kidney, testis, and lung, and considerably small in the heart, liver and intestine (Fig. 2B).

Northern blotting was performed in the following manner: The total RNA (10  $\mu$ g) was electrophoresed on a 1% agarose gel containing formaldehyde, and transferred onto Hybond-N Membrane (Amersham).

Fetal human chondrocytes cultured in the presence and absence of Bt2cAMP, various fetal human tissues (Fig. 2A), and adult tissues (Fig. 2B) were electrophoresed on a 1% agarose gel containing formaldehyde, and transferred onto a nylon membrane. The membrane was hybridized with a CDEP probe (CDEP) or a glyceraldehyde-3-phosphate dehydrogenase probe (GAPDH). To examine the tissue distribution, total

RNA of various fetal human tissues were supplied by Dr. Li Yu of Norman Bethune University of Medical Sciences. A 1.6 kb fragment of CDEP was labeled with [<sup>32</sup>P]dCTP, and used as a hybridization probe. The membrane was washed with 0.2 × SSC containing 0.5% SDS for 30 minutes at 65°C. A biomax X-ray film was exposed to light through the washed membrane using a sensitizing film at -70°C.

Nucleotide sequencing of the full length of CDEP cDNA was performed in the following manner: CDEP full length cDNA was isolated by the rapid amplification cDNA ends (RACE) method using Marathon cDNA Amplification Kit (Clontech). In detail, double-stranded cDNA was joined to Marathon cDNA adaptor, and subjected to suppression PCR. The reaction was carried out using an adaptor primer, and a gene specific primer designed for CDEP on the basis of the nucleotide sequence of CDEP. The amplified cDNA sample was separated using a 4% polyacrylamide gel, and DNA of major bands was extracted from the gel and subcloned into pGEM-T. The subcloned plasmid double-stranded DNA and a series of synthetic oligonucleotides were used as a sequencing template and specific primers, respectively. DNA sequencing was performed by the Sanger method using Sequenase 7-deaza-dGTP DNA Sequencing Kit (Amersham), or ABI PRISM 310 Autosequencer (Perkin Elmer).

The so determined nucleotide sequence of CDEP cDNA and an amino acid sequence deduced therefrom are set forth

in SEQ ID NO: 1. Only the amino acid sequence is set forth in SEQ ID NO: 2. CDEP cDNA has an open reading frame of 3135 bp. The length of 3287 bp, 3306 bp or 3442 bp, excluding the poly(A) region, agrees highly with the size (3.5 kb) of the mRNA obtained by the aforementioned northern blotting analysis. Since an in-frame stop codon exists in the 5'-region (nucleotide 34), the first ATG is admitted as an initiation codon.

#### (Example 3) Expression of CDEP mRNA in rabbit costal cartilage growth plate slices

Total RNA was extracted from each of layers, i.e., costal cartilage growth plate slices (a portion near the bone side was divided into three parts designated as G3, G2 and G1) and a resting cartilage layer (called R) of a 4-weeks-old male Japanese albino rabbit. The extract was examined for the expression level of CDEP mRNA by the RT-PCR method. The expression levels of type X collagen, alkaline phosphatase, and proteoglycan aggrecan, differentiation markers of chondrocytes, in the respective layers were confirmed by RT-PCR.

Extraction of total RNA was performed from the cartilage tissue by guanidine-cesium chloride ultracentrifugation. The RT-PCR method used SUPERScript Preamplification System (GIBCOBRL). For DNA amplification, DNA Thermal Cycler (Perkin-Elmer Cetus) was used.

Reverse transcription was performed using the total RNA (0.5  $\mu$ g) extracted from the cartilage tissue, and amplification was carried out using an upstream specific primer (5'-TCACTTCGTGGTTTCAGAGC-3') and a downstream specific primer (TCGTCTTCGCTCTCCTCAAT-3') that were designed based on the nucleotide sequence of CDEP to obtain a CDEP cDNA fragment. The conditions for the amplification reaction were set to carry out a denaturation reaction (95°C, 1 min), annealing and extension (65°C, 3 min), and 20 cycles of amplification were performed. The resulting DNA was electrophoresed for 15 minutes at 100 V on a 1% agarose gel.

PCR southern blotting was performed in the following manner: The electrophoresed DNA in the gel was denatured in a 0.5N NaOH solution containing 1.5M NaCl, and then transferred onto a nylon membrane Nytran0.45 (Schleicher & Schuell) with the use of 6 $\times$  SSC. This membrane was subjected to a hybridization reaction for 16 hours at 68°C in a hybridization solution containing a [<sup>32</sup>P]labeled CDEP probe labeled with Oligolabelling Kit (Pharmacia Biochem). After the reaction, the membrane was washed, and autoradiography was performed. The radioactivity was measured with BAS2000 Image Analyzer (Fujix).

Rabbit costal cartilage growth plate chondrocytes were cultured in the following manner: The growth plates were separated from the costal cartilages of the 4-weeks-old male Japanese albino rabbit. They were digested with 0.1%

EDTA, 0.1% trypsin containing PBS and 0.05% collagenase containing DMEM, and chondrocytes were isolated. Six-well tissue culture plates were seeded with 300,000 cells per well, and the cells were cultured with alpha MEM containing 10% bovine fetus serum. The culture medium was replaced at intervals of 2 days, starting on the 5th day of culture.

The expression of CDEP mRNA in the rabbit costal cartilage growth plate chondrocytes culture system was investigated by extracting total RNA from the cell layer on the 6th, 10th, 14th, 18th, 22nd and 26th days of culture, and determining the expression level of CDEP mRNA by RT-PCR.

The induction of CDEP mRNA by PTH in the rabbit costal cartilage growth plate chondrocytes culture system was investigated by adding PTH (1-84) ( $1 \times 10^{-7} \text{M}$ ) after 6, 10, 14, 18, 22 and 26 days of culture, incubating the system for a further 24 hours, then extracting total RNA, and determining the expression level of CDEP mRNA at each stage by RT-PCR.

The time course of the induction of CDEP mRNA expression by PTH and cAMP was investigated by adding PTH (1-84) ( $1 \times 10^{-7} \text{M}$ ) and  $\text{Bt}_2\text{cAMP}$  in rabbit costal cartilage growth plate chondrocytes on the 12th day of culturing, extracting total RNA 1, 3, 6, 12 and 24 hours later, and determining the expression level of CDEP mRNA at each time point by RT-PCR.

The results of the foregoing experiments and the results given below (Example 4) gave the following findings:  
(1) In the in vivo cartilage tissue, more CDEP is expressed

in the hypertrophic layer showing the expression of type X collagen and ALP, the markers of terminal differentiation of chondrocytes (hypertrophy, calcification) (Fig. 7, Fig. 11A, Fig. 11B). (2) In the in vitro chondrocytes culture system, more CDEP mRNA is expressed in the hypertrophic stage and later (on the 22nd day of culturing and later), and the amount of expression is further increased upon the addition of PTH using cAMP as a second messenger (Fig. 8). Furthermore, (3) the level of CDEP mRNA rises transiently at a very early stage (as early as 1 hour later) in short-term induction during the period of from 0 to 6 hours after addition of cAMP and PTH, and then rises over time (Fig. 9). Moreover, the expression in the period of from 0 to 48 hours after addition of PTH becomes biphasic (Fig. 10).

(Example 4) Intracellular localization of CDEP by immunofluorescence staining

Immunofluorescence staining was performed to investigate the localization of CDEP in the cell with the use of MRC5, a human lung fibroblast cell line. That is, 3,000 cells were seeded on a 1x1 cm cover glass, and cultured for 24 hours in DMEM. Then, cytotoxic necrotizing factor 2 (CNF2) derived from enteropathogenic E. coli was added, and the so treated cells were cultured for a further 12 hours together with a CNF2-free control group. The cultures were washed with PBS, and then fixed with 2% paraformaldehyde

for 30 minutes at room temperature. Then, the system was washed with PBS again, treated for 3 minutes with 0.5% Triton X-100, and further washed with PBS. Then, the system was incubated for 1 hour in PBS containing 5% sheep serum at room temperature to block nonspecific binding. After washing with PBS containing 0.05% Tween 20 (PBST), the system was incubated for 2 hours at room temperature along with anti-CDEP antiserum diluted 1:100 with PBS. Then, after washing with PBST, the system was incubated for 30 minutes at room temperature under light-shielded conditions together with FITC-labeled anti-rabbit sheep IgG (Cappel) diluted 1:1000. After washing with PBST, the system was observed with a confocal laser microscope (LSM410, Carl Zeiss) (Figs. 11A, 11B).

In the absence of CNF2, the cytoplasm was stained as a whole. In the presence of CNF2, polymerization of actin took place. CDEP was localized in filamentous processes and ruffling sites of the cell membrane that occurred on this occasion.

### **Industrial Applicability**

As described above, the present invention provides genes expressed specifically in differentiated human-derived chondrocytes. These genes are important not only in analyzing the mechanism of differentiation or degeneration of a cartilage, but also in developing gene



therapies for osteoarthritis and rheumatoid arthritis. Furthermore, CDEP according to the invention is expressed in cartilage and other tissues, and thus its important actions in such other tissues are suggested.

5           That is, CDEP of the invention, in view of its structural features, serves as a regulatory factor for a cytoskeleton binding to protein on a cell membrane, and also has a structure characteristic of an epistatic factor for regulating the functions of Rho. By controlling an  
10   actin-series cytoskeleton, i.e., activating Rho in response to signals from upstream to control signal transduction downstream, CDEP may maintain cell shape or regulate cell adhesion, cell aggregation, or cell motility. From the aspect of being a regulatory factor for cytoskeleton, CDEP  
15   may play important roles in the reconstruction of a cytoskeleton which occurs as a result of stimulation by cell growth factors, or cell transformation. For chondrocytes, changes in cell shape are closely related to differentiation, and it is known that differentiated chondrocytes takes a  
20   spherical form, while dedifferentiated chondrocytes is spindle-shaped. Hence, if the shape of a cell can be changed to a spherical form by accelerating or suppressing the functions of CDEP, it may be possible to induce or maintain the differentiation of chondrocytes. Gene introduction with  
25   the expectation of such an action may make it possible to control the differentiated state of chondrocytes with

deviating functions (dedifferentiated chondrocytes) in arthropathies, including osteoarthritis.

Among other Rho GEF family members, some are known to work as oncogenes by arousing such abnormalities as the lack of an amino acid on the N-terminal side. They are reported to enhance the infiltrating ability of cancer. If it is found that active type mutation, such as deficiency in part of a CDEP gene, causes canceration of a cell, a novel therapeutic drug with a specific suppressive effect may be developed with CDEP as a target.

Also, it is conceivable to prepare a dominant negative mutant of CDEP, and introduce its gene into a cancer cell to inhibit the activity of the cancer cell, thereby achieving cancer treatment. In other words, CDEP is likely to be useful in elucidating the mechanism of control of the functions of the entire Rho family.

Ezrin binds to CD44, etc. on a cell membrane at its N-terminus, and binds to actin on its C-terminal side, thereby taking part in cytoskeletal regulation. Rho is considered to regulate this binding. CDEP, which has an ezrin-like domain at the N-terminal, and DH and PH domains at the C-terminal, may bind to protein on the cell membrane at the N-terminal, and activate Rho on the C-terminal side. Thus, CDEP may be a regulatory factor for a cytoskeleton which binds to a cell membrane, and also be a factor for regulating signals to Rho by feedback of the state of the cytoskeleton.

## Claims

1. A protein specifically expressed in differentiated chondrocytes, comprising an ezrin-like domain, a Db1 domain, and a pleckstrin domain.

2. A protein having an amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing.

3. A protein comprising an amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing in which one to several amino acids have been deleted, substituted or added, the protein being specifically expressed in differentiated chondrocytes, and the protein being such that

(1) the amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 1st to 374th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 1st to 374th amino acids in the SEQ ID NO: 2,

(2) the amino acid sequence of a portion of the protein corresponding to an amino acid sequence ranging from the 544th to 737th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 544th to 737th amino acids in the SEQ ID NO: 2, and

(3) the amino acid sequence of a portion of the protein

corresponding to an amino acid sequence ranging from the 764th to 854th amino acids in SEQ ID NO: 2 in the sequence listing has homology of 85% or more to the amino acid sequence ranging from the 764th to 854th amino acids in the SEQ ID NO: 2.

4. DNA encoding the protein according to any one of claims 1 to 3.

5. A gene comprising DNA shown in the following (a) or (b):

(a) DNA comprising a nucleotide sequence ranging from the 49th to 3,183rd bases in a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing; and

(b) DNA which is hybridized under stringent conditions with DNA having a nucleotide sequence ranging from the 49th to 3,183rd bases in a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, and which encodes a protein specifically expressed in differentiated chondrocytes.

6. DNA having a part of or all of a nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, or having a nucleotide sequence complementary to the part of or all of the nucleotide sequence.

7. An antibody against the protein according to any one of claims 1 to 3.

8. A kit for screening a regulator of cell differentiation induction, the kit comprising at least one

of the following (a) to (c) as an active ingredient:

(a) the protein according to any one of claims 1 to 3;

(b) the DNA according to any one of claims 4 to 6;  
5 and

(c) the antibody according to claim 7.

9. A methods for screening a regulator of cell differentiation induction, the method comprising using the kit according to claim 8.

10 10. The method for screening claimed in claim 9, wherein the regulator of cell differentiation induction is an anti-tumor agent.

**Abstract**

The present invention provides a human chondrocyte-derived gene. That is, a protein encoded by the human chondrocyte-derived gene according to the invention has a structure characteristic of a regulatory factor for a cytoskeleton binding to protein on a cell membrane, and also an epistatic factor for regulating the functions of Rho. In detail, the protein has all of an ezrin-like domain, a DH domain, and a PH domain.

Fig.1

009250" 2463550

CGCGCAGCCGCCGCTGTGGAGATATTCTAAGCCGCTTTTCAT	120
CGCGCAGCCGCCGCTGTGGAGATATTCTAAGCCGCTTTTCAT	24
TTGGAACGTGGACAGAAGCCGCCCAACACCTTCAGGAAAACCTGTCATCAAAATCCAGATGCTGGATGACACCCAGGAGCAITTTGAAGTCCACAAAGAGCTCCTGGGAAGGTG	240
TTGGAACGTGGACAGAAGCCGCCCAACACCTTCAGGAAAACCTGTCATCAAAATCCAGATGCTGGATGACACCCAGGAGCAITTTGAAGTCCACAAAGAGCTCCTGGGAAGGTG	64
CTGCTGGATGCACTTTGCAACCACTCAACCTCGTGGAAAGTGACTATTTGGCTCGAGTTTCTGATCACAAGAGATCACGGTGGCTGGATCTCTAAACCACTTGTGAACAG	360
CTGCTGGATGCACTTTGCAACCACTCAACCTCGTGGAAAGTGACTATTTGGCTCGAGTTTCTGATCACAAGAGATCACGGTGGCTGGATCTCTAAACCACTTGTGAACAG	104
ATTAGAAGGCCAAAGCAGCTGTTGTTAAGTTTGTGGTAAATCTTTCCGCTGACACACCACTCAAGAAGAACTCACAAGGTACCTGTTCCGCTGCAGGTGAAGCAGGACTTG	480
ATTAGAAGGCCAAAGCAGCTGTTGTTAAGTTTGTGGTAAATCTTTCCGCTGACACACCACTCAAGAAGAACTCACAAGGTACCTGTTCCGCTGCAGGTGAAGCAGGACTTG	144
GCTCAAGGCAGGTTGACGTGTAATGACACAGCGCAGCTCTCTGATTTACACATTGTGCAATCTGAGATTGGGATTTTGTGAAGCCTTGGACAGAGAGCACTTAGCAAAAAATAA	600
GCTCAAGGCAGGTTGACGTGTAATGACACAGCGCAGCTCTCTGATTTACACATTGTGCAATCTGAGATTGGGATTTTGTGAAGCCTTGGACAGAGAGCACTTAGCAAAAAATAA	184
TACATACCTCAGCAAGACGCTAGAGGACAAAATCGTGAATTTACCATTAACCATTTGACAAACACCCAGCAGAATCAGATTTCCAGCTCTAGAGATTGCCGCTCGCTAGAGATG	720
TACATACCTCAGCAAGACGCTAGAGGACAAAATCGTGAATTTACCATTAACCATTTGACAAACACCCAGCAGAATCAGATTTCCAGCTCTAGAGATTGCCGCTCGCTAGAGATG	224
YATGGAATCCGTTGACCCCGGCAAGGACAGGACGAGGACGAGTCAATCTGGCGTTGCCAACACGGGAATTTAGTGTTCAGGGTTTCACTAAGATCAATGCTTCAACTGGGCC	840
YATGGAATCCGTTGACCCCGGCAAGGACAGGACGAGGACGAGTCAATCTGGCGTTGCCAACACGGGAATTTAGTGTTCAGGGTTTCACTAAGATCAATGCTTCAACTGGGCC	264
AAGGTGCGGAAGCTGAGCTTCAAGAGGAAGCGCTTTCTCATCAAGCTCGCGCAGATGCAATAGTGGTACCAAGATACCTTGGAAATCTGATGGCAGTGGGATTTCTGCAAGTCC	960
AAGGTGCGGAAGCTGAGCTTCAAGAGGAAGCGCTTTCTCATCAAGCTCGCGCAGATGCAATAGTGGTACCAAGATACCTTGGAAATCTGATGGCAGTGGGATTTCTGCAAGTCC	304
TTCTGGAATCTGTGTTGAACATCATGCTCTTTAGACTTTTGAAGAGCCCAACCAAGCCGCTCTTTAGCTGGGGGTCATCATTTCCGTTCACTGGTGGGACTCAG	1080
TTCTGGAATCTGTGTTGAACATCATGCTCTTTAGACTTTTGAAGAGCCCAACCAAGCCGCTCTTTAGCTGGGGGTCATCATTTCCGTTCACTGGTGGGACTCAG	344
AAGCAGGTTCTCGACTATGTTAAAGAGGAGGACATAAGAAGGTGCAGTTTGAAGGAAGCAGCAGCAAGATTCATCTCGGAGCCTTCTTACAGCCTACAGAACTGAATTCGAA	1200
AAGCAGGTTCTCGACTATGTTAAAGAGGAGGACATAAGAAGGTGCAGTTTGAAGGAAGCAGCAGCAAGATTCATCTCGGAGCCTTCTTACAGCCTACAGAACTGAATTCGAA	384
GTGCTGGAGCAGTCTCAGCAGAGCACCAGCCTTACATTTGGAGAGGTCGCGAATCTCCAGGGGGCAGAGCTGCCGCGAGGAAAGGAACCGAAGGTTTCCGCGGGGAGCCGGGTCG	1320
GTGCTGGAGCAGTCTCAGCAGAGCACCAGCCTTACATTTGGAGAGGTCGCGAATCTCCAGGGGGCAGAGCTGCCGCGAGGAAAGGAACCGAAGGTTTCCGCGGGGAGCCGGGTCG	424
CACCGAGCCCTGCGCCGAGGAGAGCCCGCGGGTAAACAGCAGGCGGACGGAGCCGCTCGGCGCCACGAGGAGAGGAGGAGGTCGTTAAGGATAGGACCCAGCAGAGTAACCT	1440
CACCGAGCCCTGCGCCGAGGAGAGCCCGCGGGTAAACAGCAGGCGGACGGAGCCGCTCGGCGCCACGAGGAGAGGAGGAGGTCGTTAAGGATAGGACCCAGCAGAGTAACCT	464
CAGCCCGCAGCCAGCAGCAGGCTCCCTGACTGGCAGTCTCACCTTTCCGAGCTGTGTGAACTCAGAGGGGGAGTGGCCCTGCCAACGTCGACTTGTCTCCCACTGAGCCCC	1560
CAGCCCGCAGCCAGCAGCAGGCTCCCTGACTGGCAGTCTCACCTTTCCGAGCTGTGTGAACTCAGAGGGGGAGTGGCCCTGCCAACGTCGACTTGTCTCCCACTGAGCCCC	504
GACACCAAGCAGGCTCTCCCTGATCAGCCGCTGTGTAATGACACAGGCTGCCCGGACGAGCATGAGGATGAGGGCCGAGGAGAGGATTCCCAACTGATAAGCGTACTTCTATA	1680
GACACCAAGCAGGCTCTCCCTGATCAGCCGCTGTGTAATGACACAGGCTGCCCGGACGAGCATGAGGATGAGGGCCGAGGAGAGGATTCCCAACTGATAAGCGTACTTCTATA	544
GCTAAGGAAGTGTCTACCAAGCAGCAGATATCTGAAGGATCTCGAAGTATCACTTCTGTTGTTTCAAGCAGATGAGCAAGAGGAGCGCATGCCGGAAGCAGTGAAGTCTCTATA	1800
GCTAAGGAAGTGTCTACCAAGCAGCAGATATCTGAAGGATCTCGAAGTATCACTTCTGTTGTTTCAAGCAGATGAGCAAGAGGAGCGCATGCCGGAAGCAGTGAAGTCTCTATA	584
TTCCCGAATTTTGAACCTTTGACAAATTTTCACTAATTTCTCAAGGAAATTGAGCAACGACTTGCCTGTGGGAAGGCGCTCAATGCCCAGATCAGAGATTACCAAGAACTCGGC	1920
TTCCCGAATTTTGAACCTTTGACAAATTTTCACTAATTTCTCAAGGAAATTGAGCAACGACTTGCCTGTGGGAAGGCGCTCAATGCCCAGATCAGAGATTACCAAGAACTCGGC	624
GATGTCATGCTGAAGAATTCAGGGCAGTGAAGCAGCTGGCGGCTCACCTGTGGAAGCAGCAGGAGCTTGGAGGCGCTGGAGAATGAAGTCCAGAGCTCCCGCGGCTGGAGAACTTC	2040
GATGTCATGCTGAAGAATTCAGGGCAGTGAAGCAGCTGGCGGCTCACCTGTGGAAGCAGCAGGAGCTTGGAGGCGCTGGAGAATGAAGTCCAGAGCTCCCGCGGCTGGAGAACTTC	664
TGCAGAGACTTTGAGCTGCAGAGGTTGTTTACCTACCGCTCAACACCTTCTCTCGGCGCTGACGAGTCACTGAGTCAAGCAGGTCCTGGAGCGGCTGTGCAACACCAACCCG	2160
TGCAGAGACTTTGAGCTGCAGAGGTTGTTTACCTACCGCTCAACACCTTCTCTCGGCGCTGACGAGTCACTGAGTCAAGCAGGTCCTGGAGCGGCTGTGCAACACCAACCCG	704
CCGAGCCACGCCGACTTCAGGGACTGCGAGCGCGCTTTGGCAGAGATCAGGAGATGGTGGCAGCTCCAGGTCAGATGATCAAGATGGAGAAATTCAGAGCTGCAGCACTCAAG	2280
CCGAGCCACGCCGACTTCAGGGACTGCGAGCGCGCTTTGGCAGAGATCAGGAGATGGTGGCAGCTCCAGGTCAGATGATCAAGATGGAGAAATTCAGAGCTGCAGCACTCAAG	744
AAAGATTGATTGGCATTGACAATCTTGTGGTTCCGGGAAGGAGGATTCATCCGTCTGGGCGAGCTCAGCAAGCTCTCGGGGAAGGGGCTCCAGCAGCGCATGTTCTCTGTTCAACGAC	2400
AAAGATTGATTGGCATTGACAATCTTGTGGTTCCGGGAAGGAGGATTCATCCGTCTGGGCGAGCTCAGCAAGCTCTCGGGGAAGGGGCTCCAGCAGCGCATGTTCTCTGTTCAACGAC	784
GTCCTGTATACAGAGCGGGGGCTGACGGCTCCAATCAGTTTAAAGTCCACGGGAGCTCCGCTCTATGGCATGACGATTGAGGAGAGCGAAGAGAGTGGGGGGTCCCCACTGC	2520
GTCCTGTATACAGAGCGGGGGCTGACGGCTCCAATCAGTTTAAAGTCCACGGGAGCTCCGCTCTATGGCATGACGATTGAGGAGAGCGAAGAGAGTGGGGGGTCCCCACTGC	824
CTGACCCCTCGGGGCGAGCGGCTCATCATCTGTCGCGCCAGTTCTCGGTCCGAGATGGAGAAGTGGGTTGAGGACATCCAGATGGCCATTGACCTGGCGGAGAAGAGCAGCAGCCCC	2640
CTGACCCCTCGGGGCGAGCGGCTCATCATCTGTCGCGCCAGTTCTCGGTCCGAGATGGAGAAGTGGGTTGAGGACATCCAGATGGCCATTGACCTGGCGGAGAAGAGCAGCAGCCCC	864
GCCCTGAGTTCTGGCAGCAGCCCCCTGACAACAGTCCCTGATGAAGCCACCGGCTGACCAAGGATGAGGATGACCTGAGCGCTCGCGACATCGCTGGAGCGCCAGGCGC	2760
GCCCTGAGTTCTGGCAGCAGCCCCCTGACAACAGTCCCTGATGAAGCCACCGGCTGACCAAGGATGAGGATGACCTGAGCGCTCGCGACATCGCTGGAGCGCCAGGCGC	904
CCGACCCGCGGCAACACAATGGTGACGTGTGCTGGCAGCAGCAACACCGCTCTCATGGTGGATTCAGCATCGCATGGAGAATCAGTTGCTGGAAACCTGCTGAGGAAATCAAA	2880
CCGACCCGCGGCAACACAATGGTGACGTGTGCTGGCAGCAGCAACACCGCTCTCATGGTGGATTCAGCATCGCATGGAGAATCAGTTGCTGGAAACCTGCTGAGGAAATCAAA	944
AACAGCAGCGGGTGGCAGAGCTGTGGGTGGTGTTCACAACTTCTGCTGTTCTTACAAATCACCAGGACCAATCATCCCTTCCAGCCTGCTCTGCTGCTGCTACTGCTCAAC	3000
AACAGCAGCGGGTGGCAGAGCTGTGGGTGGTGTTCACAACTTCTGCTGTTCTTACAAATCACCAGGACCAATCATCCCTTCCAGCCTGCTCTGCTGCTGCTACTGCTCAAC	984
ATCCCTCTGAGTCCGAGAATCCAGAAAGACTACGTGTTCAAGTGCACCTCAAGTCCCAGCTTACTACTTACGGGCGGAAAGCGAGTACAGTTCGAAAGGTGGATGGAAGTATC	3120
ATCCCTCTGAGTCCGAGAATCCAGAAAGACTACGTGTTCAAGTGCACCTCAAGTCCCAGCTTACTACTTACGGGCGGAAAGCGAGTACAGTTCGAAAGGTGGATGGAAGTATC	1024
CGCAGTGCCACGAGCTGCTCGCTCGCGACCCACGTGTTGAGCCACAAGAGTCTCTGTTGATTGATGGCGGACACACTCGTTTCCGAGTGGCTGCTTCTGCTGGAAGACGTTTCTTT	3240
CGCAGTGCCACGAGCTGCTCGCTCGCGACCCACGTGTTGAGCCACAAGAGTCTCTGTTGATTGATGGCGGACACACTCGTTTCCGAGTGGCTGCTTCTGCTGGAAGACGTTTCTTT	1045
CTTCTGTATTAATGAAGCCTGGTAAATTAACACCTGTGAAATCAAAACATGGCTTCCAGCAGCTCTCTGTCTCCACAGCCGCTTTTTTAAACCCGACCTCTCAGCGTTTGAA	3360
CTTCTGTATTAATGAAGCCTGGTAAATTAACACCTGTGAAATCAAAACATGGCTTCCAGCAGCTCTCTGTCTCCACAGCCGCTTTTTTAAACCCGACCTCTCAGCGTTTGAA	
TGAACAGCGCTCCACCTCCAGCTCGCATCCGCTGGGGCGCTGTTCTTTAGCTAGTGCCAGTATTAACAACTTGTCAAT	3442



**Fig.2A****Fig.2B**



Fig.3


CDEP	1	MGEIEQRPTPGSRGAPENSGISTLERGQKPPPTPSGKLVSIKIQMLDDTQEA FEVPQRAP.GKV L
Ezrin	1	.....MPKPINVRVTT...MDAELEFA..IQNTT GKQL
Band 4.1	1	.....MHCKVSLDDTVYEC.VVEKHAKGQDL
CDEP	66	LDVAVCNHLNLVEGDYFGLFPPDHKKITVWLDLLKPIVKQIRRPKHVVVK.FVVKFFPPDHTQLQEE
Ezrin	30	FDQVVKTI GLREVVTYGLHYVDNKGFP T W L K D K K V S A Q E V R K E N P L O F K F R A K F Y P E D V A E E L I Q
Band 4.1	27	LKRVCEHLNLL EEDYFGLAIW D N A T S K T W L D S A K E I K K Q . V R . G V P W N F T F N V K F Y P P D P A Q L T E D
CDEP	131	LTRY.LFALQVKQDLAQGR LTCNDTSAALLISHIVQSEIGDFD.EALDREHLAKNKYIPQQ.....
Ezrin	95	DITQKLFLLQVKEGILSDEIYCPPE T A V L L G S Y A V Q A K F G D Y N K E V H K S G Y L S S E R L I P Q R V M D Q H
Band 4.1	91	ITRY Y L C . L Q L R Q D I V A G R L P C S F A T L A L L G S Y T I Q S E L G D Y D P E L H G V D Y V S D F K L A P N Q . . . . .
CDEP	190	....DALEDKIVEFHHNHIGQTPAESDFQLLEIARRLEMYGIRLHPAKDREGTKINLAVANTGILV
Ezrin	161	KLTRDQWEDRIQVWHAEHGRMLKDNAMLEYL K I A Q D L E M Y G I N Y F E I K N K K G T D L W L G V D A L G L N I
Band 4.1	151	...TKELEEKVMELHKSYRSMTPAQADLEFLENAKKLSMYGVDLHKAKDLEGVDIILGVCSSGLLV
CDEP	252	FQGF TK I N A . . . F N W A K V R K L S F K R K R F L I K L R P D A N S A Y Q D T L E F L M A S R D F C K S F W K I C V E H H A
Ezrin	227	YEKDDKLT PKIGFPWSEIRNISFNDDKFFVIKPIDKKAPDF...VFYAPRLRINKRILQLCMGNHE
Band 4.1	214	YDKL R I N R . . . F P W P K V L K I S Y K R S S F F I K I R P G E Q E Q Y E S T I G F K L P S Y R A A K K L W K V C V E H H T
CDEP	315	FFRLFEEPKPKPVLF SRGSSFRFSGRTQKQVLDYVKEGGHKKVQ.FERKHSKIHSIRS.L
Ezrin	289	LYMRRRKPD TIEVQOMKAQAREKH...QKLERQQL ETEKRR ETVEREKEQMMREKEEL
Band 4.1	277	FFRLTS.TDTIFSKFLALGSKFRYSGRTQAQTRQASALIDRPAPH.FERTASKRAS.RS.L

009250" 24E5560


Fig.4

CDEP	544	I A K E V S T T E R T Y L K D L E V I T S W F Q S T V S K E . . . . . D A M P E A L . . . . . K S L I F P N F E P L H K F H T N F L K .
Db1	499	V L N E L I Q T E R V V R E L Y T V L L G Y R A E M D N P E M F D L M P P L R N K K D I L F G N M A E I Y E F H N D I F L S .
Ost	446	V M N E L L D T E R A Y V E E L L C V L E G Y A A E M D N P L M A H L I S T G L Q N K N I L F G N M E E I Y H F H N R I F L R .
Ect2	281	V A K E L Y Q T E S N Y V N I L A T I I Q L F Q V P L E E E G Q R G P I L A P E E I K T . I F G S I P D I F D V H M K I K D . .
FGD1	376	I A N E L L Q T E K A Y V S R L H L L D Q V F C A R L L E A . . R N R S S F P A D V V H G I F S N I C S I Y C F H Q Q . F L L P
CDEP	601	E I E Q R L A L W E G R S N A Q I R D Y Q R I G D V M L K N I Q G M K H L A A H L M K H S E A L E A L E N G I K S S R R L E N F C
Db1	563	S L E N C A H A . . . . . P E R V G P C F L E R . K D F Q M Y A K Y C Q N K P R S E T I W R K Y S E . . . . . C
Ost	510	E L E S C I D C . . . . . P E L V G R C F L E R . M E E F Q I Y E K Y C Q N K P R S E S L W R Q C S D . . . . . C
Ect2	343	D L E D L I A N W D E . . . . . S R S I G D I F L K Y A K D L V K T Y P P F V N F F E M S K E M I K C E K . . Q K P R F H
FGD1	439	E L E K R M E E W D R . . . . . Y P R I G D I L Q L A P F L K M Y G E Y V K N F D R A V E L V N T W T E R S T Q F K V I I
CDEP	666	R D F . E L Q K V C Y . . . . . L P L N T F L L R P L H R L M H Y K Q V L . E R L C K H P P S H A D F R D C R A A L A E I T E M V A
Db1	609	A F F Q E C Q R K L K H R . L R L D S Y L L K P V Q R I T K Y Q L L L K E . L L K Y S K D C E G S A . L L K K A L D A M L D L . .
Ost	556	P F F Q E C Q K L D H K . . . . . L S L D S Y L L K P V Q R I T K Y Q L L L K E . M L K Y S K H C E G A E . D L Q E A L S S I L G I . .
Ect2	400	A F L K I N Q A K P E C G R Q S I V E L L I R F V Q R L P S V A L L N D . L K K H T A D E N P D K S T L E K A I G S L K E V . .
FGD1	496	H . . . . . E V Q K E E A C G N I T L Q H H M L E P V Q R I P R Y E L L K D Y L L K L P H G S . P D S K D A Q K S L E L I A T A . .
CDEP	726	Q L H G T M I K M E N F
Db1	669	. . . . . L K S V N D
Ost	616	. . . . . L K A V N D
Ect2	460	. . . . . M T H I N D
FGD1	555	. . . . . A E H S N A


**Fig.5**



**Fig.6**





0092250" 24CCE560


**Fig.7**

009250" 24E5560



**Fig.8**



**Fig.9**





**Fig.11A****CNF2 (-)****Fig.11B****CNF2 (+)**

# COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

ATTORNEY DOCKET NO.:

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## HUMAN FETUS CHONDROCYTE-DERIVED GENE

the specification of which:

is attached hereto; or

was filed as United States application Serial No. \_\_\_\_\_ on \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable); or

was filed as PCT international application Number PCT/JP98/05348 on November 27, 1998 and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

### PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Japan	342060/1997	27 November 1997	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

Combined Declaration For Patent Application and Power of Attorney - (Continued)  
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.:

I hereby claim the benefits under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.

U.S. FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. APPLICATIONS

STATUS (Check One)

U.S. APPLICATION NO.

U.S. FILING DATE

PATENTED

PENDING

ABANDONED

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

Direct Telephone Calls To:  
(name and telephone number)

**John G. Smith**  
**202-467-7613**

## Combined Declaration For Patent Application and Power of Attorney - (Continued)

(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	Yukio KATO	
RESIDENCE & CITIZENSHIP	Hiroshima, Japan JPX	COUNTRY OF CITIZENSHIP: Japan
POST OFFICE ADDRESS	6-9-501, Ushitawaseda 3-chome, Higashi-ku, Hiroshima-shi, Hiroshima 732-0062 Japan	
FIRST OR SOLE INVENTOR'S SIGNATURE:	<i>Yukio Kato</i>	DATE: May 12, 2000
FULL NAME OF SECOND INVENTOR	Takeshi KAWAMOTO	
RESIDENCE & CITIZENSHIP	Yamaguchi, Japan JPX	COUNTRY OF CITIZENSHIP: Japan
POST OFFICE ADDRESS	2580-17, Ajisu-cho, Yoshiki-gun, Yamaguchi 754-1200 Japan	
SECOND INVENTOR'S SIGNATURE:	<i>Takeshi Kawamoto</i>	DATE: May 12, 2000
FULL NAME OF THIRD INVENTOR	Yasuhiko KOYANO	
RESIDENCE & CITIZENSHIP	Hiroshima, Japan JPX	COUNTRY OF CITIZENSHIP: Japan
POST OFFICE ADDRESS	14-24-405, Nishiasahi-machi, Minami-ku, Hiroshima-shi, Hiroshima 734-0002 Japan	
THIRD INVENTOR'S SIGNATURE:	<i>Yasuhiko Koyano</i>	DATE: May 12, 2000
FULL NAME OF FOURTH INVENTOR		
RESIDENCE & CITIZENSHIP		COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS		
FOURTH INVENTOR'S SIGNATURE		DATE

Listing of Inventors Continued on attached page(s)

[ ] Yes

[ X ] No

## SEQUENCE LISTING

&lt;110&gt; CHUGAI SEIYAKU KABUSHIKI KAISHA

5 &lt;120&gt; cDNA and deduced amino acid sequence in human fetus chondrocytes

&lt;130&gt; CGS98-04PCT

10 &lt;160&gt; 22

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

15 &lt;211&gt; 3442

&lt;212&gt; DNA

&lt;213&gt; Homo sapiense

20 &lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (49)..(3183)

&lt;400&gt; 1

25 cgccgcagcc gccggcgtg tggagatatt ctctaagccg ctttcac atg gga gaa 57  
 Met Gly Glu  
 1

30 ata gag cag agg ccg acc cca gga tca cga ctg ggg gcc ccg gaa aat 105  
 Ile Glu Gln Arg Pro Thr Pro Gly Ser Arg Leu Gly Ala Pro Glu Asn  
 5 10 15

35 tcg ggg atc agt acc ttg gaa cgt gga cag aag ccg ccc cca aca cct 153  
 Ser Gly Ile Ser Thr Leu Glu Arg Gly Gln Lys Pro Pro Pro Thr Pro  
 20 25 30 35

40 tca gga aaa ctc gtg tcc atc aaa atc cag atg ctg gat gac acc cag 201  
 Ser Gly Lys Leu Val Ser Ile Lys Ile Gln Met Leu Asp Asp Thr Gln  
 40 45 50

45 gag gca ttt gaa gtt cca caa aga gct cct ggg aag gtg ctg ctg gat 249  
 Glu Ala Phe Glu Val Pro Gln Arg Ala Pro Gly Lys Val Leu Leu Asp  
 55 60 65

45 gca gtt tgc aac cac ctc aac ctc gtg gaa ggt gac tat ttt ggc ctc 297

Ala	Val	Cys	Asn	His	Leu	Asn	Leu	Val	Glu	Gly	Asp	Tyr	Phe	Gly	Leu		
70						75						80					
gag	ttt	cct	gat	cac	aaa	aag	atc	acg	gtg	tgg	ctg	gat	ctc	cta	aaa	345	
Glu	Phe	Pro	Asp	His	Lys	Lys	Ile	Thr	Val	Trp	Leu	Asp	Leu	Leu	Lys		
85						90						95					
ccc	att	gtg	aaa	cag	att	aga	agg	cca	aag	cac	gtt	gtt	gtt	aag	ttt	393	
Pro	Ile	Val	Lys	Gln	Ile	Arg	Arg	Pro	Lys	His	Val	Val	Val	Lys	Phe		
100						105						110			115		
gtg	gtg	aaa	ttc	ttt	ccg	cct	gac	cac	aca	caa	ctc	caa	gaa	gaa	ctc	441	
Val	Val	Lys	Phe	Phe	Pro	Pro	Asp	His	Thr	Gln	Leu	Gln	Glu	Glu	Leu		
			120						125						130		
aca	agg	tac	ctg	ttc	gcg	ctg	cag	gtg	aag	cag	gac	ttg	gct	caa	ggc	489	
Thr	Arg	Tyr	Leu	Phe	Ala	Leu	Gln	Val	Lys	Gln	Asp	Leu	Ala	Gln	Gly		
			135						140						145		
agg	ttg	acg	tgt	aat	gac	acc	agc	gca	gct	ctc	ttg	att	tca	cac	att	537	
Arg	Leu	Thr	Cys	Asn	Asp	Thr	Ser	Ala	Ala	Leu	Leu	Ile	Ser	His	Ile		
			150						155						160		
gtg	caa	tct	gag	att	ggg	gat	ttt	gat	gaa	gcc	ttg	gac	aga	gag	cac	585	
Val	Gln	Ser	Glu	Ile	Gly	Asp	Phe	Asp	Glu	Ala	Leu	Asp	Arg	Glu	His		
			165			170						175					
tta	gca	aaa	aat	aaa	tac	ata	cct	cag	caa	gac	gca	cta	gag	gac	aaa	633	
Leu	Ala	Lys	Asn	Lys	Tyr	Ile	Pro	Gln	Gln	Asp	Ala	Leu	Glu	Asp	Lys		
180						185						190			195		
atc	gtg	gaa	ttt	cac	cat	aac	cac	att	gga	caa	aca	cca	gca	gaa	tca	681	
Ile	Val	Glu	Phe	His	His	Asn	His	Ile	Gly	Gln	Thr	Pro	Ala	Glu	Ser		
			200						205						210		
gat	ttc	cag	ctc	cta	gag	att	gcc	cgt	cgg	cta	gag	atg	tat	gga	atc	729	
Asp	Phe	Gln	Leu	Leu	Glu	Ile	Ala	Arg	Arg	Leu	Glu	Met	Tyr	Gly	Ile		
			215						220						225		
cgg	ttg	cac	ccg	gcc	aag	gac	agg	gaa	ggc	acg	aag	atc	aat	ctg	gcc	777	
Arg	Leu	His	Pro	Ala	Lys	Asp	Arg	Glu	Gly	Thr	Lys	Ile	Asn	Leu	Ala		
			230						235						240		
gtt	gcc	aac	acg	gga	att	cta	gtg	ttt	cag	ggt	ttc	act	aag	atc	aat	825	
Val	Ala	Asn	Thr	Gly	Ile	Leu	Val	Phe	Gln	Gly	Phe	Thr	Lys	Ile	Asn		

	245	250	255	
5	gcc ttc aac tgg gcc aag gtg cgg aag ctg agc ttc aag agg aag cgc Ala Phe Asn Trp Ala Lys Val Arg Lys Leu Ser Phe Lys Arg Lys Arg 260 265 270 275			873
10	ttt ctc atc aag ctc cgg cca gat gcc aat agt gcg tac cag gat acc Phe Leu Ile Lys Leu Arg Pro Asp Ala Asn Ser Ala Tyr Gln Asp Thr 280 285 290			921
15	ttg gaa ttc ctg atg gcc agt cgg gat ttc tgc aag tcc ttc tgg aaa Leu Glu Phe Leu Met Ala Ser Arg Asp Phe Cys Lys Ser Phe Trp Lys 295 300 305			969
20	atc tgt gtt gaa cat cat gcc ttc ttt aga ctt ttt gaa gag ccc aaa Ile Cys Val Glu His His Ala Phe Phe Arg Leu Phe Glu Glu Pro Lys 310 315 320			1017
25	cca aag ccc aag ccc gtc ctc ttt agc cgg ggg tca tca ttt cgg ttc Pro Lys Pro Lys Pro Val Leu Phe Ser Arg Gly Ser Ser Phe Arg Phe 325 330 335			1065
30	agt ggt cgg act cag aag cag gtt ctc gac tat gtt aaa gaa gga gga Ser Gly Arg Thr Gln Lys Gln Val Leu Asp Tyr Val Lys Glu Gly Gly 340 345 350 355			1113
35	cat aag aag gtg cag ttt gaa agg aag cac agc aag att cat tct atc His Lys Lys Val Gln Phe Glu Arg Lys His Ser Lys Ile His Ser Ile 360 365 370			1161
40	cgg agc ctt gct tca cag cct aca gaa ctg aat tcg gaa gtg ctg gag Arg Ser Leu Ala Ser Gln Pro Thr Glu Leu Asn Ser Glu Val Leu Glu 375 380 385			1209
45	cag tct cag cag agc acc agc ctt aca ttt gga gaa ggt gcc gaa tct Gln Ser Gln Gln Ser Thr Ser Leu Thr Phe Gly Glu Gly Ala Glu Ser 390 395 400			1257
50	cca ggg ggc cag agc tgc cgg cga gga aag gaa ccg aag gtt tcc gcc Pro Gly Gly Gln Ser Cys Arg Arg Gly Lys Glu Pro Lys Val Ser Ala 405 410 415			1305
55	ggg gag ccg ggg tcg cac ccg agc cct gcg ccg agg aga agc ccc gcg Gly Glu Pro Gly Ser His Pro Ser Pro Ala Pro Arg Arg Ser Pro Ala 420 425 430 435			1353

	ggt aac aag cag gcg gac gga gcc gcc tcg gcg ccc acg gag gaa gag	1401
	Gly Asn Lys Gln Ala Asp Gly Ala Ala Ser Ala Pro Thr Glu Glu Glu	
	440 445 450	
5		
	gag gag gtc gtt aag gat agg acc cag cag agt aaa cct cag ccc ccg	1449
	Glu Glu Val Val Lys Asp Arg Thr Gln Gln Ser Lys Pro Gln Pro Pro	
	455 460 465	
10		
	cag cca agc aca ggc tcc ctg act ggc agt cct cac ctt tcc gag ctg	1497
	Gln Pro Ser Thr Gly Ser Leu Thr Gly Ser Pro His Leu Ser Glu Leu	
	470 475 480	
15		
	tct gtg aac tcg cag ggg gga gtg gcc cct gcc aac gtg acc ttg tct	1545
	Ser Val Asn Ser Gln Gly Gly Val Ala Pro Ala Asn Val Thr Leu Ser	
	485 490 495	
20		
	ccc aac ctg agc ccc gac acc aag cag gcc tct ccc ttg atc agc ccg	1593
	Pro Asn Leu Ser Pro Asp Thr Lys Gln Ala Ser Pro Leu Ile Ser Pro	
	500 505 510 515	
25		
	ctg ctg aat gac cag gcc tgc ccc cgg acg gac gat gag gat gag ggc	1641
	Leu Leu Asn Asp Gln Ala Cys Pro Arg Thr Asp Asp Glu Asp Glu Gly	
	520 525 530	
30		
	cgg agg aag aga ttc cca act gat aaa gcg tac ttc ata gct aag gaa	1689
	Arg Arg Lys Arg Phe Pro Thr Asp Lys Ala Tyr Phe Ile Ala Lys Glu	
	535 540 545	
35		
	gtg tct acc acc gag cga aca tat ctg aag gat ctc gaa gtt atc act	1737
	Val Ser Thr Thr Glu Arg Thr Tyr Leu Lys Asp Leu Glu Val Ile Thr	
	550 555 560	
40		
	tcg tgg ttt cag agc aca gtg agc aaa gag gac gcc atg ccg gaa gca	1785
	Ser Trp Phe Gln Ser Thr Val Ser Lys Glu Asp Ala Met Pro Glu Ala	
	565 570 575	
45		
	ctg aaa agt ctc ata ttc ccg aat ttt gaa cct ttg cac aaa ttt cat	1833
	Leu Lys Ser Leu Ile Phe Pro Asn Phe Glu Pro Leu His Lys Phe His	
	580 585 590 595	
50		
	act aat ttt ctc aag gaa att gag caa cga ctt gcc ctg tgg gaa ggc	1881
	Thr Asn Phe Leu Lys Glu Ile Glu Gln Arg Leu Ala Leu Trp Glu Gly	
	600 605 610	



	cgc tca aat gcc caa atc aga gat tac caa aga atc ggc gat gtc atg	1929
	Arg Ser Asn Ala Gln Ile Arg Asp Tyr Gln Arg Ile Gly Asp Val Met	
	615 620 625	
5	ctg aag aac att cag ggc atg aag cac ctg gcg gct cac ctg tgg aag	1977
	Leu Lys Asn Ile Gln Gly Met Lys His Leu Ala Ala His Leu Trp Lys	
	630 635 640	
10	cac agc gag gcc ttg gag gcc ctg gag aat gga atc aag agc tcc cgg	2025
	His Ser Glu Ala Leu Glu Ala Leu Glu Asn Gly Ile Lys Ser Ser Arg	
	645 650 655	
15	cgg ctg gag aac ttc tgc aga gac ttt gag ctg cag aag gtg tgt tac	2073
	Arg Leu Glu Asn Phe Cys Arg Asp Phe Glu Leu Gln Lys Val Cys Tyr	
	660 665 670 675	
20	cta ccg ctc aac acc ttc ctc ctg cgg cca ctg cac cgg ctc atg cac	2121
	Leu Pro Leu Asn Thr Phe Leu Leu Arg Pro Leu His Arg Leu Met His	
	680 685 690	
25	tac aag cag gtc ctg gag cgg ctg tgc aaa cac cac ccg ccg agc cac	2169
	Tyr Lys Gln Val Leu Glu Arg Leu Cys Lys His His Pro Pro Ser His	
	695 700 705	
30	gtg gca cag ctc cac ggt acg atg atc aag atg gag aat ttc cag aag	2217
	Ala Asp Phe Arg Asp Cys Arg Ala Ala Leu Ala Glu Ile Thr Glu Met	
	710 715 720	
35	gtg gca cag ctc cac ggt acg atg atc aag atg gag aat ttc cag aag	2265
	Val Ala Gln Leu His Gly Thr Met Ile Lys Met Glu Asn Phe Gln Lys	
	725 730 735	
40	ctg cac gaa ctc aag aaa gat ttg att ggc att gac aat ctt gtg gtt	2313
	Leu His Glu Leu Lys Lys Asp Leu Ile Gly Ile Asp Asn Leu Val Val	
	740 745 750 755	
45	ccg gga agg gag ttc atc cgt ctg ggc agc ctc agc aag ctc tcg ggg	2361
	Pro Gly Arg Glu Phe Ile Arg Leu Gly Ser Leu Ser Lys Leu Ser Gly	
	760 765 770	
50	aag ggg ctc cag cag cgc atg ttc ttc ctg ttc aac gac gtc ctg cta	2409
	Lys Gly Leu Gln Gln Arg Met Phe Phe Leu Phe Asn Asp Val Leu Leu	
	775 780 785	
55	tac acg agc cgg ggg ctg acg gcc tcc aat cag ttt aaa gtc cac ggg	2457

	Tyr	Thr	Ser	Arg	Gly	Leu	Thr	Ala	Ser	Asn	Gln	Phe	Lys	Val	His	Gly	
	790				795				800								
5	cag	ctc	ccg	ctc	tat	ggc	atg	acg	att	gag	gag	agc	gaa	gac	gag	tgg	2505
	Gln	Leu	Pro	Leu	Tyr	Gly	Met	Thr	Ile	Glu	Glu	Ser	Glu	Asp	Glu	Trp	
	805				810				815								
10	ggg	gtg	ccc	cac	tgc	ctg	acc	ctc	cgg	ggc	cag	cgg	cag	tcc	atc	atc	2553
	Gly	Val	Pro	His	Cys	Leu	Thr	Leu	Arg	Gly	Gln	Arg	Gln	Ser	Ile	Ile	
	820				825				830				835				
15	gtg	gcc	gcc	agt	tct	cgg	tcc	gag	atg	gag	aag	tgg	gtt	gag	gac	atc	2601
	Val	Ala	Ala	Ser	Ser	Arg	Ser	Glu	Met	Glu	Lys	Trp	Val	Glu	Asp	Ile	
	840				845				850								
20	cag	atg	gcc	att	gac	ctg	gcg	gag	aag	agc	agc	agc	ccc	gcc	cct	gag	2649
	Gln	Met	Ala	Ile	Asp	Leu	Ala	Glu	Lys	Ser	Ser	Ser	Pro	Ala	Pro	Glu	
	855				860				865								
25	ttc	ctg	gcc	agc	agc	ccc	cct	gac	aac	aag	tcc	cct	gat	gaa	gcc	acc	2697
	Phe	Leu	Ala	Ser	Ser	Pro	Pro	Asp	Asn	Lys	Ser	Pro	Asp	Glu	Ala	Thr	
	870				875				880								
30	gcg	gct	gac	cag	gag	tca	gag	gat	gac	ctg	agc	gcc	tcg	cgc	aca	tcg	2745
	Ala	Ala	Asp	Gln	Glu	Ser	Glu	Asp	Asp	Leu	Ser	Ala	Ser	Arg	Thr	Ser	
	885				890				895								
35	ctg	gag	cgc	cag	gcc	ccg	cac	cgc	ggc	aac	aca	atg	gtg	cac	gtg	tgc	2793
	Leu	Glu	Arg	Gln	Ala	Pro	His	Arg	Gly	Asn	Thr	Met	Val	His	Val	Cys	
	900				905				910				915				
40	tgg	cac	cgc	aac	acc	agc	gtc	tcc	atg	gtg	gac	ttc	agc	atc	gca	gtg	2841
	Trp	His	Arg	Asn	Thr	Ser	Val	Ser	Met	Val	Asp	Phe	Ser	Ile	Ala	Val	
	920				925				930								
45	gag	aat	cag	ttg	tct	gga	aac	ctg	ctg	agg	aaa	ttc	aaa	aac	agc	aac	2889
	Glu	Asn	Gln	Leu	Ser	Gly	Asn	Leu	Leu	Arg	Lys	Phe	Lys	Asn	Ser	Asn	
	935				940				945								
50	ggg	tgg	cag	aag	ctg	tgg	gtg	gtg	ttc	aca	aac	ttc	tgc	ctg	ttc	ttc	2937
	Gly	Trp	Gln	Lys	Leu	Trp	Val	Val	Phe	Thr	Asn	Phe	Cys	Leu	Phe	Phe	
	950				955				960								
55	tac	aaa	tca	cac	cag	gac	aat	cat	ccc	ctt	gcc	agc	ctg	cct	ctg	ctc	2985
	Tyr	Lys	Ser	His	Gln	Asp	Asn	His	Pro	Leu	Ala	Ser	Leu	Pro	Leu	Leu	

	965	970	975	
	ggc tac tgc ctc acc atc ccc tct gag tcc gag aac atc cag aaa gac			3033
	Gly Tyr Ser Leu Thr Ile Pro Ser Glu Ser Glu Asn Ile Gln Lys Asp			
5	980	985	990	995
	tac gtg ttc aag ctg cac ttc aag tcc cac gtc tac tac ttc agg gcg			3081
	Tyr Val Phe Lys Leu His Phe Lys Ser His Val Tyr Tyr Phe Arg Ala			
10	1000	1005	1010	
	gaa agc gag tac acg ttc gaa agg tgg atg gaa gtg atc cgc agt gcc			3129
	Glu Ser Glu Tyr Thr Phe Glu Arg Trp Met Glu Val Ile Arg Ser Ala			
	1015	1020	1025	
15	acc agc tct gcc tgc cga ccc cac gtg ttg agc cac aaa gag tct ctt			3177
	Thr Ser Ser Ala Ser Arg Pro His Val Leu Ser His Lys Glu Ser Leu			
	1030	1035	1040	
20	gtg tat tgatggccgg acacactcgt ttccgcagtg gctgctttcc tggaagacgt			3233
	Val Tyr			
	1045			
	ttcctttctt ctgtattaat gaagcctggt aaaattaaca cctgtctgaa aatcaaaaac			3293
25	atggcttccc agcagctctc ctgtctccac agccgcgttt ttttaaccccg acctctcagc			3353
	gtttgaatga acagcgtcc cacctccagt cctggcatcc gctgggggcg ctgttcttta			3413
	gctagtgccca gtattaaaac attgtcatt			3442
30				
	<210> 2			
	<211> 1045			
	<212> PRT			
35	<213> Homo sapiens			
	<400> 2			
	Met Gly Glu Ile Glu Gln Arg Pro Thr Pro Gly Ser Arg Leu Gly Ala			
	1 5 10 15			
40	Pro Glu Asn Ser Gly Ile Ser Thr Leu Glu Arg Gly Gln Lys Pro Pro			
	20 25 30			
	Pro Thr Pro Ser Gly Lys Leu Val Ser Ile Lys Ile Gln Met Leu Asp			
45	35 40 45			

009250" 246550

	Asp Thr Gln Glu Ala Phe Glu Val Pro Gln Arg Ala Pro Gly Lys Val	
	50 55 60	
5	Leu Leu Asp Ala Val Cys Asn His Leu Asn Leu Val Glu Gly Asp Tyr	
	65 70 75 80	
	Phe Gly Leu Glu Phe Pro Asp His Lys Lys Ile Thr Val Trp Leu Asp	
	85 90 95	
10	Leu Leu Lys Pro Ile Val Lys Gln Ile Arg Arg Pro Lys His Val Val	
	100 105 110	
	Val Lys Phe Val Val Lys Phe Phe Pro Pro Asp His Thr Gln Leu Gln	
15	115 120 125	
	Glu Glu Leu Thr Arg Tyr Leu Phe Ala Leu Gln Val Lys Gln Asp Leu	
	130 135 140	
20	Ala Gln Gly Arg Leu Thr Cys Asn Asp Thr Ser Ala Ala Leu Leu Ile	
	145 150 155 160	
	Ser His Ile Val Gln Ser Glu Ile Gly Asp Phe Asp Glu Ala Leu Asp	
	165 170 175	
25	Arg Glu His Leu Ala Lys Asn Lys Tyr Ile Pro Gln Gln Asp Ala Leu	
	180 185 190	
	Glu Asp Lys Ile Val Glu Phe His His Asn His Ile Gly Gln Thr Pro	
30	195 200 205	
	Ala Glu Ser Asp Phe Gln Leu Leu Glu Ile Ala Arg Arg Leu Glu Met	
	210 215 220	
35	Tyr Gly Ile Arg Leu His Pro Ala Lys Asp Arg Glu Gly Thr Lys Ile	
	225 230 235 240	
	Asn Leu Ala Val Ala Asn Thr Gly Ile Leu Val Phe Gln Gly Phe Thr	
	245 250 255	
40	Lys Ile Asn Ala Phe Asn Trp Ala Lys Val Arg Lys Leu Ser Phe Lys	
	260 265 270	
	Arg Lys Arg Phe Leu Ile Lys Leu Arg Pro Asp Ala Asn Ser Ala Tyr	
45	275 280 285	

	Gln Asp Thr Leu Glu Phe Leu Met Ala Ser Arg Asp Phe Cys Lys Ser	
	290	295 300
5	Phe Trp Lys Ile Cys Val Glu His His Ala Phe Phe Arg Leu Phe Glu	
	305	310 315 320
	Glu Pro Lys Pro Lys Pro Lys Pro Val Leu Phe Ser Arg Gly Ser Ser	
		325 330 335
10	Phe Arg Phe Ser Gly Arg Thr Gln Lys Gln Val Leu Asp Tyr Val Lys	
		340 345 350
	Glu Gly Gly His Lys Lys Val Gln Phe Glu Arg Lys His Ser Lys Ile	
15		355 360 365
	His Ser Ile Arg Ser Leu Ala Ser Gln Pro Thr Glu Leu Asn Ser Glu	
		370 375 380
20	Val Leu Glu Gln Ser Gln Gln Ser Thr Ser Leu Thr Phe Gly Glu Gly	
		385 390 395 400
	Ala Glu Ser Pro Gly Gly Gln Ser Cys Arg Arg Gly Lys Glu Pro Lys	
		405 410 415
25	Val Ser Ala Gly Glu Pro Gly Ser His Pro Ser Pro Ala Pro Arg Arg	
		420 425 430
	Ser Pro Ala Gly Asn Lys Gln Ala Asp Gly Ala Ala Ser Ala Pro Thr	
30		435 440 445
	Glu Glu Glu Glu Glu Val Val Lys Asp Arg Thr Gln Gln Ser Lys Pro	
		450 455 460
35	Gln Pro Pro Gln Pro Ser Thr Gly Ser Leu Thr Gly Ser Pro His Leu	
		465 470 475 480
	Ser Glu Leu Ser Val Asn Ser Gln Gly Gly Val Ala Pro Ala Asn Val	
		485 490 495
40	Thr Leu Ser Pro Asn Leu Ser Pro Asp Thr Lys Gln Ala Ser Pro Leu	
		500 505 510
	Ile Ser Pro Leu Leu Asn Asp Gln Ala Cys Pro Arg Thr Asp Asp Glu	
45		515 520 525

	Asp	Glu	Gly	Arg	Arg	Lys	Arg	Phe	Pro	Thr	Asp	Lys	Ala	Tyr	Phe	Ile	
	530						535					540					
5	Ala	Lys	Glu	Val	Ser	Thr	Thr	Glu	Arg	Thr	Tyr	Leu	Lys	Asp	Leu	Glu	
	545					550					555					560	
	Val	Ile	Thr	Ser	Trp	Phe	Gln	Ser	Thr	Val	Ser	Lys	Glu	Asp	Ala	Met	
					565					570					575		
10	Pro	Glu	Ala	Leu	Lys	Ser	Leu	Ile	Phe	Pro	Asn	Phe	Glu	Pro	Leu	His	
				580					585					590			
	Lys	Phe	His	Thr	Asn	Phe	Leu	Lys	Glu	Ile	Glu	Gln	Arg	Leu	Ala	Leu	
15			595					600					605				
	Trp	Glu	Gly	Arg	Ser	Asn	Ala	Gln	Ile	Arg	Asp	Tyr	Gln	Arg	Ile	Gly	
	610					615						620					
20	Asp	Val	Met	Leu	Lys	Asn	Ile	Gln	Gly	Met	Lys	His	Leu	Ala	Ala	His	
	625					630					635					640	
	Leu	Trp	Lys	His	Ser	Glu	Ala	Leu	Glu	Ala	Leu	Glu	Asn	Gly	Ile	Lys	
					645					650					655		
25	Ser	Ser	Arg	Arg	Leu	Glu	Asn	Phe	Cys	Arg	Asp	Phe	Glu	Leu	Gln	Lys	
				660					665						670		
	Val	Cys	Tyr	Leu	Pro	Leu	Asn	Thr	Phe	Leu	Leu	Arg	Pro	Leu	His	Arg	
30			675					680					685				
	Leu	Met	His	Tyr	Lys	Gln	Val	Leu	Glu	Arg	Leu	Cys	Lys	His	His	Pro	
	690						695					700					
35	Pro	Ser	His	Ala	Asp	Phe	Arg	Asp	Cys	Arg	Ala	Ala	Leu	Ala	Glu	Ile	
	705					710					715					720	
	Thr	Glu	Met	Val	Ala	Gln	Leu	His	Gly	Thr	Met	Ile	Lys	Met	Glu	Asn	
					725					730					735		
40	Phe	Gln	Lys	Leu	His	Glu	Leu	Lys	Lys	Asp	Leu	Ile	Gly	Ile	Asp	Asn	
				740					745					750			
	Leu	Val	Val	Pro	Gly	Arg	Glu	Phe	Ile	Arg	Leu	Gly	Ser	Leu	Ser	Lys	
45			755					760					765				

009250" 2455550

	Leu Ser Gly Lys Gly Leu Gln Gln Arg Met Phe Phe Leu Phe Asn Asp	770	775	780
5	Val Leu Leu Tyr Thr Ser Arg Gly Leu Thr Ala Ser Asn Gln Phe Lys	785	790	795 800
	Val His Gly Gln Leu Pro Leu Tyr Gly Met Thr Ile Glu Glu Ser Glu	805	810	815
10	Asp Glu Trp Gly Val Pro His Cys Leu Thr Leu Arg Gly Gln Arg Gln	820	825	830
	Ser Ile Ile Val Ala Ala Ser Ser Arg Ser Glu Met Glu Lys Trp Val	835	840	845
15	Glu Asp Ile Gln Met Ala Ile Asp Leu Ala Glu Lys Ser Ser Ser Pro	850	855	860
	Ala Pro Glu Phe Leu Ala Ser Ser Pro Pro Asp Asn Lys Ser Pro Asp	865	870	875 880
	Glu Ala Thr Ala Ala Asp Gln Glu Ser Glu Asp Asp Leu Ser Ala Ser	885	890	895
20	Arg Thr Ser Leu Glu Arg Gln Ala Pro His Arg Gly Asn Thr Met Val	900	905	910
	His Val Cys Trp His Arg Asn Thr Ser Val Ser Met Val Asp Phe Ser	915	920	925
25	Ile Ala Val Glu Asn Gln Leu Ser Gly Asn Leu Leu Arg Lys Phe Lys	930	935	940
	Asn Ser Asn Gly Trp Gln Lys Leu Trp Val Val Phe Thr Asn Phe Cys	945	950	955 960
	Leu Phe Phe Tyr Lys Ser His Gln Asp Asn His Pro Leu Ala Ser Leu	965	970	975
30	Pro Leu Leu Gly Tyr Ser Leu Thr Ile Pro Ser Glu Ser Glu Asn Ile	980	985	990
	Gln Lys Asp Tyr Val Phe Lys Leu His Phe Lys Ser His Val Tyr Tyr	995	1000	1005
35				
40				
45				





	<212> DNA
	<213> Artificial
5	<220> <223> probe
	<400> 6 aaagacctca ccctccatct 20
10	<210> 7 <211> 20 <212> DNA <213> Artificial
15	<220> <223> probe
20	<400> 7 gtcgattacg tggagagcta 20
25	<210> 8 <211> 20 <212> DNA <213> Artificial
30	<220> <223> probe
	<400> 8 atgaacttct tcaccagctc 20
35	<210> 9 <211> 20 <212> DNA <213> Artificial
	<220> <223> probe
40	<400> 9 gtcaaggctg agaacgggaa 20
	<210> 10
45	<211> 20

**COPIES OF THE REPORT**

5

10

15

20

25

30

35

40

45

	<210> 14
	<211> 20
	<212> DNA
5	<213> Artificial
	<220>
	<223> probe
10	<400> 14
	ttggagttgt gtgtggtcag 20
	<210> 15
15	<211> 25
	<212> DNA
	<213> Artificial
	<220>
20	<223> probe
	<400> 15
	gccaaaatag tcaccttcca cgagg 25
25	<210> 16
	<211> 20
	<212> DNA
	<213> Artificial
30	<220>
	<223> probe
	<400> 16
35	ccttcaggaa aactcgtgtc 20
	<210> 17
	<211> 29
40	<212> DNA
	<213> Artificial
	<220>
	<223> probe
45	



<220>  
<223> probe

5 <400> 21  
tcacttcgtg gtttcagagc 20

<210> 22

10 <211> 20  
<212> DNA  
<213> Artificial

15 <220>  
<223> probe

<400> 22  
tcgtcttcgc tctcctcaat 20